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Abstract
The United States is in an opioid epidemic. The comitant use of opiates and benzodiazepines can
ultimately result in death. This project consisted of a quality improvement approach addressing
the continued need to educate prescribers on coprescribing benzodiazepines and opioids to the
adult population. A qualitative and quantitative descriptive analysis was utilized for data
collection. The results will assist in determining if accessing the Prescription Drug Monitoring
Program (PDMP) and utilizing evidence-based guidelines before prescribing treatment compared
to the nonutilization of the PDMP and evidence-based guidelines aid in the reduction of
mortality and overdose rates within a three-month period. The significance of this project was
aimed at increasing the use of the PDMP in providing treatment to patients. The recognition of
the misuse and abuse of opioids and benzodiazepines, concurrently, indicate the need for a
higher level of care and alternative treatment options, therefore, assisting in the reduction in the
mortality and overdose rate.
Keywords: opioids, benzodiazepines, misuse, substance use disorder, prescription drug
monitoring program (PDMP), substance use treatment provider, primary care provider
(PCP), Nurse practitioner (NP), Physician assistant (PA), pain specialist, psychiatrist, and
pharmacist

v
Table of Contents
Acknowledgments............................................................................................................... ii
Abstract .............................................................................................................................. iv
List of Tables ................................................................................................................... viii
List of Figures .................................................................................................................... ix
Chapter 1: Introduction ........................................................................................................1
Problem of Interest .........................................................................................................2
Background of POI ........................................................................................................3
Purpose of the Project ..............................................................................................4
Significance of POI ........................................................................................................4
Nature of Project ............................................................................................................5
Research Question (PICOT Format) ..............................................................................7
Hypothesis (Restatement of the PICOT) .......................................................................9
Theoretical Framework Discussion ...............................................................................9
Operational Definitions ................................................................................................10
Scope of Project ...........................................................................................................12
Chapter Summary ........................................................................................................13
Chapter 2: Literature Search Methods ...............................................................................15
Literature Review Discussion ......................................................................................15
Theoretical Framework Discussion .............................................................................24
Chapter Summary ........................................................................................................25
Chapter 3: Research Method ..............................................................................................27
Project Design ..............................................................................................................28
Measurement Tool .......................................................................................................28
Reliability and Variability............................................................................................29
Data Collection and Analysis.......................................................................................29
Methodology ................................................................................................................31
Findings........................................................................................................................32
Feasibility and Appropriateness ...................................................................................32
IRB Approval and Process ...........................................................................................32
Interprofessional Collaboration ...................................................................................34
Practice Setting ............................................................................................................36
Target Population .........................................................................................................36
Risks and Benefits........................................................................................................36
Timeline .......................................................................................................................38
Chapter Summary ........................................................................................................39
Chapter 4: Findings ............................................................................................................40

vi
Project Analysis ...........................................................................................................40
Discussion of Demographics .......................................................................................40
Data Analysis ...............................................................................................................41
Question Guiding the Inquiry ......................................................................................43
Data Analysis Summary ..............................................................................................75
Limitations of the Project.............................................................................................77
Interpretation and Inference of the Findings ................................................................78
Chapter Summary ........................................................................................................84
Chapter 5: Discussion of Conclusions and Recommendations..........................................86
Implications of Analysis for Leaders ...........................................................................87
EBP Findings and Relationship to DNP Essentials (I-VIII) ........................................90
Essential I: Scientific Underpinnings.....................................................................90
Essential II. Organizational and Systems Leadership for Quality Improvement and
Systems Thinking.......................................................................................91
Essential III. Clinical Scholarship and Analytical Methods for Evidence-Based
Practice .......................................................................................................91
Essential IV. Information System/Technology for the Improvement and
Transformation of Health ...........................................................................91
Essential V. Health Care Policy for Advocacy in Health Care ..............................92
Essential VI. Interprofessional Collaboration for Improving Patient Population
and Population Outcomes ..........................................................................92
Essential VII. Clinical Prevention and Population Health for Improving the
Nation’s Health ..........................................................................................92
Essential VIII. Advanced Nursing Practice ...........................................................93
Recommendations for Future Research and Clinical Practice .....................................93
Chapter Summary ........................................................................................................94
References ..........................................................................................................................96
Appendix A: Digital Permission ......................................................................................107
Appendix B: Survey Tool Permission .............................................................................111
Appendix C: Permission Letter Response .......................................................................112
Appendix D: Survey Tool ................................................................................................113
Appendix E: Survey Questions and Raw Frequencies ....................................................114
Appendix F: MD Specialties Included and Excluded From Sample ...............................123
Appendix G: Site Permissions .........................................................................................125
Appendix H: NIH/IRB Training Certificate ....................................................................127
Appendix I: Human Subjects Research Projections ........................................................128

vii
Appendix J: Online Research Ethics Course ...................................................................129
Appendix K: IRB Approval Letter ..................................................................................130
Appendix L: IRB Data Deactivation Letter .....................................................................131
Appendix M: Results of the Survey Tool (RAW Data) ...................................................132

viii
List of Tables
Table 1. DNP Project Timeline and Task List ...................................................................38

ix
List of Figures
Figure 1. Updated Version of the Middle Range Theory of Unpleasant Symptoms .........25
Figure 2. Survey Overview ................................................................................................41
Figure 3. Knowledge of the PDMP....................................................................................44
Figure 4. PDMP Management of Prescription-Controlled Substances .............................45
Figure 5. Registering and Accessing the PDMP ................................................................46
Figure 6. Communication Between Providers ...................................................................47
Figure 7. Impact of the PDMP ...........................................................................................47
Figure 8. Benefits Compared to the Drawbacks of the PDMP ..........................................48
Figure 9. Monitoring Patient’s-Controlled Substance Prescriptions .................................49
Figure 10. Control Patient Doctor Shopping .....................................................................50
Figure 11. Provider Communication .................................................................................51
Figure 12. Management of Patient Prescriptions ...............................................................52
Figure 13. Registering and Accessing the PDMP ..............................................................53
Figure 14. Increase Provider Communication ...................................................................54
Figure 15. PDMP Impact ...................................................................................................54
Figure 16. Benefits and Drawbacks of the PDMP .............................................................55
Figure 17. Monitoring Patient’s-Controlled Substance Prescriptions ...............................56
Figure 18. Control Doctor Shopping .................................................................................57
Figure 19. Provider Consults .............................................................................................58
Figure 20. Use of the PDMP ..............................................................................................59
Figure 21. Ease of Patient Access ......................................................................................59
Figure 22. Asscessed Patients via PDMP ..........................................................................60

x
Figure 23. Reasons for Accessing the PDMP ...................................................................61
Figure 24. Barriers for Not Using the PDMP ...................................................................62
Figure 25. Internet Limiting PDMP Access ......................................................................62
Figure 26. Limitations of Time ..........................................................................................63
Figure 27. Nonbeneficial to Office ....................................................................................63
Figure 28. Support Staff Has No Access ...........................................................................64
Figure 29. Lack of Training ...............................................................................................64
Figure 30. Difficulty Using PDMP ....................................................................................65
Figure 31. Actions Resulting From Utilization of the PDMP ...........................................66
Figure 32. Who Do You Communicate More? ..................................................................67
Figure 33. Number of Clinicians in the Office ..................................................................67
Figure 34. Providers Writing Prescriptions .......................................................................68
Figure 35. Pharmacists .......................................................................................................68
Figure 36. Patients .............................................................................................................69
Figure 37. Topics Most Communicated On .......................................................................69
Figure 38. Additional Resources........................................................................................70
Figure 39. Guidelines Around Pain Management..............................................................71
Figure 40. Advice for Patients With Mental Health and Substance Abuse Disorders ......72
Figure 41. Recommendations for Seeing Patients With Mental Health and Substance
Abuse Disorders .........................................................................................................72
Figure 42. Patients With Dual Mental Health and Substance Abuse Disorders ................73
Figure 43. Referrals for Substance Abuse .........................................................................74
Figure 44. Patient Interaction .............................................................................................74

1
Chapter 1: Introduction
The United States is in the middle of a substance abuse crisis. The misuse and abuse rate
of prescription drugs involving opioids is continually rising. According to the Georgia Senate
White Paper (2016), the opioid related overdose deaths in the United States has risen 200% since
the year 2000. In 2005, opioids were responsible for more than 28,470 deaths. In the same year,
12.5 million Americans reported the misuse of pain medication. According to the Centers for
Disease Control and Prevention (CDC; 2017), benzodiazepines accounted for a 13% increase of
the opioid-analgesic poisoning deaths in 1999 and were involved in 31% of the opioid-analgesic
poisoning deaths in 2011. Benzodiazepine, another prescription drug used for anxiety, also
played a significant role in the substance abuse crisis.
Opiates and benzodiazepines are both very potent drugs. Concomitantly, these drugs can
cause a decrease in the function of the central nervous system (CNS) resulting in a decrease or
slowing of respiration, sedation, objective impairment, psychomotor effects, cognitive
impairment (e.g., learning and memory), coma, and death (Parhami et al., 2015). The
combination of opioids and benzodiazepines are commonly prescribed drugs and are a major
cause of the increase in mortality in the United States. In 2014, 81 million patients were
dispensed an opioid, and 30 million patients were dispensed a benzodiazepine (Hwang et al.,
2016). According to the Drug Abuse Warning Network (DAWN), the National Vital Statics
System indicate from 2004-2011, opioids and benzodiazepines are the largest contributors to
emergency room (ER) visits. The report indicated ER visits due to the illicit use of opioids and
benzodiazepines increased from 11.0 to 34.2 per 100,000 population (Jones & McAninch, 2015).
The misuse of opioids and associated disorders has cost the United States an estimated $78.5
billion in 2010 (CDC, 2017).
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Despite the overwhelming crisis, physicians are providing prescription drugs at an
alarming rate. Other risk factors include: doctor shopping (i.e., receiving overlapping
prescriptions from multiple providers and pharmacies), obtaining the prescription drug from a
family member or friend for recreational use, taking high daily doses of prescription pain
relievers, having mental illness or a history of substance misuse, being low-income, and living in
rural and urban areas (CDC, 2017).
Problem of Interest
The concurrent use of opioids and benzodiazepines have been described as a lethal
combination. Opioids and benzodiazepines have a synergistic effect that causes the body’s
mechanism to slow down and produces a sense of euphoria. In order to maintain this state of
euphoria, increasing amounts of these drugs must be concomitantly ingested. Concurrent use of
these drugs is more like taking three or four times the prescribed dose (American Addiction
Centers, 2019).
The current statistics on the substance abuse crisis involving the opioid crisis continues to
rise at an alarming rate. In efforts to identify causative factors aiding the continuous progression
of the substance abuse crisis, Simon et al. (2019) conducted a retrospective study on the
“Concomitant Dichotomous variables use of opioids and benzodiazepines in the outpatient
setting.” The study concluded:
1. clinicians may not be aware of patients concurrently taking opioids and benzodiazepines,
2. emphasized the importance of checking the Prescription Drug Monitoring Program
(PDMP) regularly, and
3. utilizing the information from the PDMP to make fully informed decisions regarding the
safest possible way to prescribe controlled substances. (Simon et al., 2019, pp. 341–342)
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Upon analyzing the results of the aforementioned study, the Problem of Interest (POI) for this
project will focus on Prescribers coprescribing benzodiazepines and opioids leading to an
increase in opioid and benzodiazepine overdose and resulting in increased mortality rates.
Background of POI
According to the CDC (2017), from 1999 to 2014, the sale of prescription opioids in the
U.S. has quadrupled. There has been no overall change in the amount of pain being reported. It
has been estimated that 1 out of 5 patients with non-cancer pain or a pain related diagnosis are
prescribed opioids in office-based-settings. From 2007 to 2012, the rate of opioid prescribing has
increased related to specialists who are managing acute and chronic pain. Primary care accounts
for approximately half of the opioid pain reliever prescriptions. In 2012, the state of Georgia,
82.2-95% of the adult population received opioid prescriptions for chronic noncancer pain (CDC,
2017).
In a report completed by the Department of Health and Human Services (H.H.S; n.d.), the
driving forces behind the substance abuse epidemic have been attributed to:
1. Prescribing trends – there has been an increase in the number of prescriptions, the
quantity of the medication, and the duration.
2. High volume prescribing – a majority of the prescriptions come from specific
prescribers.
•

General prescribing – prescribers prescribing out of their scope of practice (primary care
treating pain management without proper training).

•

Pill mills –unethical prescribing habits.

•

Emergency departments and hospitals – prescribing medications unaware of the patient’s
full prescription history.
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•

Pharmacies – fill large quantities of medicines without validating the legitimacy of the
prescription.

•

Insurers and pharmacy benefit managers – covering controlled substances as first-line
because it is inexpensive. and

•

General patients and the public – prescribing a higher number of controlled medications
with shorter administration frequencies (e.g., every 4 hours instead of every 8 hours) and
patients receiving medicines from friends and family. (pp. 13–17)

Purpose of the Project
The purpose of this project was to provide education to health care providers on the ease
of using the Prescription Drug Monitoring Program (PDMP). The educational goal is “to
improve the understanding and the dangers of concurrent prescription drug abuse activities, bring
awareness to current initiatives, and identify alternatives to ensure the safe use of prescriptions
drugs with the potential for abuse and the treatment of prescription drug dependence” (HHS.,
n.d.).
Significance of POI
Prescription drug misuse has cost the U.S. millions of dollars. In the period between 1993
and 2014, the number of opioid analgesic prescriptions dispensed from retail pharmacies in the
United States increased from approximately 113 million to 264 million (Pezalla et al., 2017),
with a corresponding increase in opioid-related diversion abuse, and deaths between 2002 and
2010 (Dart et al., 2015). Similarly, between 1996 and 2013, the percentage of U.S. adults who
filled a prescription for benzodiazepine increased from 4.1% to 5.6%, and the rate of deaths
attributed to benzodiazepines overdoses increased from 0.58 to 3.07 per 1,000,000 adults
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(Bachhuber et al., 2016; Hirschtritt et al., 2018). The CDC (2020b) reported the United States
spent approximately 1.02 trillion dollars on opioid overdose deaths and the opioid use disorder.
Despite the package inserts placed in all opioid and benzodiazepine medications and the
newly drafted guidelines issued by the FDA and the CDC, cautioning healthcare providers to
avoid coprescription of these medications, data is indicating these warnings are being ignored
(Babalonis & Walsh, 2015). In a prescriber-level analysis performed by Hwang et al. (2016),
data showed that approximately half of the patients with a concomitant opioid-benzodiazepine
episode filled an opioid and benzodiazepine prescription from the same prescriber on the same
day and in some practices the prescriptions were written by multiple providers within the
practice. The specializations that attributed to these negative behaviors were “family (18%),
internal medicine (15%), and emergency medicine (5%), with psychiatrists (3%) and pain
specialist (0.3%) representing a small percentage of concomitant prescribers” (Hwang et al.,
2016, pp. 153–154).
In response to the growing misuse and abuse of the prescription drug epidemic, the CDC
has recommended prescription drug-monitoring programs, patient review, restriction programs,
health care provider accountability, laws to prevent prescription drug abuse and prevention, and
better access to substance abuse treatment (Jann et al., 2014). According to Jann et al. (2014), it
is imperative for all healthcare professonials to be educated in using evidence-based guidelines
to improve medical practices when prescribing opioid analgesics and benzodiazepines.
Nature of Project
According to the Department of Health and Human Services (HHS; n.d.), provider
education is listed as one of the eight domains of the current HHS prescription drug activities.
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Education and training in both pain management and substance abuse, especially how to
identify patients who may be at risk for abuse and ensure patients treated with opioids
receive the appropriate dose and quantity of medication for their condition, are important
to address the significant percentage of providers who may be contributing to abuse and
overdose because of a lack of training in these areas. (HHS., n.d., p. 23)
The HHS also provides a list of clinical practice tools to assist healthcare providers in the
reduction of misuse and abuse of controlled substances. The Prescription Drug Monitoring
Program (PDMP) was documented as “one of the most promising clinical tools to address
prescription drug abuse. This program is designed to monitor prescribing of controlled
substances and can provide a prescriber or pharmacist with critical information regarding a
patient’s prescription history” (HHS, n.d., p. 25).
This project focused on the use of the PDMP as a tool to guide evidence-based treatment
for patients who misuse and abuse prescription medications. A bring your own brown bag Lunch
n’ Learn seminar was performed during the lunch hour. The presentation included data on the
misuse and abuse of prescription medications and the steps that can be taken to assist in lowering
the rates of abuse. Healthcare providers were educated on the significance of the PDMP, how to
access the database, the risks, and benefits of its use, and how to clinically incorporate the PDMP
into their evidenced-based treatment plans to provide the best quality of care. Healthcare
providers were informed about the various opportunities to enhance their knowledge and gain
continuing medical education via various HHS clinical practice tools offered, such as
NIDAMED, an interactive clinical decision-making tool.
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Research Question (PICOT Format)
In lieu of the overwhelming data presented on the misuse and abuse of prescription drugs,
federal regulations, and proposed disciplinary actions from the licensing boards some healthcare
providers are still not 100% on board with the use of the PDMP. The Multnomah County Health
Department and Oregon Health Authority surveyed providers on the use of the PDMP. The
results of the survey indicated out of the 62% of the respondents, 20% found difficulties
registering to use the system and 18% found problems accessing patient information (Orpdmp,
2013). Healthcare providers stated their lack of use resulted from, not having enough time
(40%), lack of access for support staff (31%), and the system not being easy to use (17%;
Orpdmp, 2013).
The lack of training, time constraints, and general unfamiliarity of PDMPs have shown to
be significant barriers to its use (Mospan, n.d.).
PDMP data are best used in conjunction with other resources of information, including
clinical assessment, before making any determinations about aberrant behavior, because
no validated and standardized criteria for the threshold of questionable activity has been
established. When PDMP data, combined with other information, indicate that a patient
may be engaging in the aberrant behavior, the practitioner can use this information in the
medical setting with the patient as a basis for an immediate conversation or intervention.
(SAMHSA, 2017, p. 4)
Based on the information obtained, a PICOT template will be used to gather information
during the research process. PICOT is a formula in which clinical practices can be broken into
specific questions in order to further research and explore effective therapy (Guyatt et al., 2008).
Guyatt and his colleagues (2008) explained PICOT as:
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•

(P) – Population refers to the sample of subjects you wish to recruit for your study.

•

(I) – Intervention refers to the treatment that will be provided to subjects enrolled in your
study.

•

(C) – Comparison identifies what you plan on using as a reference group to compare with
your treatment intervention.

•

(O) – Outcome represents what result you plan on measuring to examine the
effectiveness of your intervention.

•

(T) – Time describes the duration for your data collection.
The PICOT question for this project was, For prescribers that coprescribe

benzodiazepines and opioids to the adult population how does accessing the Prescription Drug
Monitoring Program (PDMP) prior to prescribing treatment compared to not accessing the
PDMP when prescribing opioids and benzodiazepines decrease the incidents of the misuse and
abuse of prescription medications in a 3-month period?
Upon the completion of the three-month survey, the providers were reeducated about the
importance of utilizing the PDMP in the clinical decision-making process and its utilization
within the treatment plan. The participants were then given a survey requesting a review of their
experience using the PDMP.
In a study of the PDMP’s use in the ED, clinicians’ review of the PDMP data changed
their clinical management in 41% of the cases. Of these cases, 61% received fewer or no
opioids than the clinician originally planned to prescribe before reviewing the PDMP
data, and 39% received more opioid medication than previously planned because the
clinician was able to confirm the patient did not have a recent history of Opioid use.
(HHS, 2013, p. 11)
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The HHS nonpeer reviewed literature on PDMPs suggest that proactive reporting reduces
doctor shopping by increasing awareness among providers about at-risk patients and
subsequently changing their prescribing behaviors. Surveys have shown the PDMP as a useful
tool for surveillance, reducing drug diversion, and has changed the way clinicians prescribe once
they have seen these reports (HHS, 2013).
Hypothesis (Restatement of the PICOT)
After conducting an extensive literary review for this scholarly project, the following
PICOT question was chosen: For prescribers that coprescribe benzodiazepines and opioids to the
adult population (P) how does accessing the Prescription Drug Monitoring Program (PDMP)
prior to prescribing treatment (I) compared to not accessing the PDMP when prescribing opioids
and benzodiazepines (C) decrease the incidents of the coprescribing of prescription medications
(O) in a 3-month period (T)?
Theoretical Framework Discussion
The theoretical framework used in this project was based on the middle-range theory of
unpleasant symptoms (TOUS) created by Lenz et al. (1997). In this theory, it is suggested that
any alterations in symptom quality, intensity, timing, and distress via physiologic, situational, or
psychological factors will alter patient outcomes (Nguyen et al., 2017). The utilization of TOUS
should guide healthcare providers to “ask questions, “such as “What is the symptom experience
like for you?” (i.e., quality, intensity, timing, and distress); “Are there other symptoms that occur
when you are having this particular symptom?”; “What contributes to making the symptom
better or worse?” (i.e., physiological, psychological, and situational factors); or “What effect
does the symptom have on your everyday life?” (i.e., performance; Nguyen et al., 2017, p. 5)
when assessing patients. It is imperative for healthcare providers to understand and “consider
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factors that might influence more than one symptom and the ways in which symptoms interact
with each other” (Lenz et al., 1997, p. 14) in order guide and improve decision-making processes
and to provide better evidenced-based care. The goal of the healthcare provider is to have a
better understanding of the dangers of coprescribing benzodiazepines and opioids, the factors
that contribute to the overdose and increase in mortality rates, increase their knowledge base
regarding the purpose and benefits of the prescription monitoring program, and recognize
alternative treatments for patients instead of coprescribing opioids and benzodiazepines.
Operational Definitions
As aforementioned, the United States is in a current state of crisis dealing with the
increased misuse and abuse of opioids and other controlled substances. In efforts to decrease the
crisis, the Prescription Drug Monitoring Program (PDMP) was developed. The PDMP “provides
law enforcement and other public agencies with surveillance data to identify providers
inappropriately prescribing controlled medications” (SAMHSA, 2017, p. 1). The population
targeted by the PDMP consists of:
•

substance use treatment providers,

•

primary care providers,

•

nurse practitioners,

•

physician assistants,

•

pain specialists,

•

psychiatrists, and

•

pharmacists (SAMHSA, 2017).
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Therefore, for the purpose of the project and to fully grasp the importance of the PDMP
and it function in healthcare aimed at providing the best evidence-based treatments and the
highest quality of care, the following keywords have been defined.
Benzodiazepines. Drugs used to treat a range of conditions, including anxiety, and
insomnia (https://www.rxlist.com/benzodiazepines/drugs-condition.htm)
Misuse. Taking medication in a manner or dose other than prescribed
(https://www.drugabuse.gov).
Nurse practitioners (NP). Master prepared practitioners (AANP, 2017) who prescribe
and/or dispense controlled medications to patients suffering from substance abuse (SAMHSA,
2017).
Opioids. Drugs that act on the nervous system to relieve pain (U.S. Food and Drug
Administration, 2021).
Pain specialists. Health care providers that prescribe controlled substances to patients
suffering from chronic pain (Tolba et al., 2018).
Pharmacists. Board certified health care professionals that dispense medications. They
“are responsible for: the quality of medicines supplied to patients, ensuring that the medicines
prescribed to patients are suitable, advising patients about medicines, including how to take
them, what reactions may occur, and answering patients' questions” (Blouin & Adams, 2017, pp.
165–166).
Physician assistant (PA). A health care provider, under the supervision of a psychiatrist,
treats patients of addiction/mental health on an inpatient or outpatient basis
(www.physicianassistantedu.org, 2019).
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Prescription drug monitoring program (PDMP). A state-wide database monitoring
system used to track the prescribing and dispensing of controlled prescription drugs to patients
(HHS, n.d.).
Primary care providers (PCP). A group of health care providers providing integrated,
accessible health care services to families and the community (SAMHSA, 1997).
Psychiatrists. Board certified doctors that treat patients suffering from substance
dependence and mental health issues (Freed, 2010).
Substance abuse disorder. Harmful or hazardous substances that can lead to dependence
syndrome and sometimes a physical withdrawal state (PDMP, 2013).
Substance use treatment providers. Clinicians specializing in substance use disorders
and provide care to patients within the community behavioral health clinics (CCBHC;
SAMSHA, 2017).
Thus, the purpose of the PDMP was to “help healthcare providers make the most
informed prescribing and dispensing decisions, as part of an initiative to address opioid-related
overdoses and deaths.” Utilization of the PDMP as intended, “can enhance clinical decision
making and improve individual patient safety while also helping curb the public health crises of
prescription drug misuse and unintentional overdose deaths” (SAMHSA, 2017, pp. 7–8).
Scope of Project
The project involved healthcare providers employed in Community Health Clinics. The
educational training on the PDMP and survey lasted three months. Reevaluation consisted of
health care providers and their experience with the use of the PDMP.
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Chapter Summary
Currently, the coprescription of benzodiazepines and opioids are being reported in such
high numbers; the nation has declared it an epidemic. The concomitant use of opioids and
benzodiazepines resulting from prescribers coprescribing can lead to death. (Hwang et al., 2016).
Therefore, the CDC and FDA have joined forces to implement new guidelines on prescribing
controlled substances to protect the general public, issue warnings on the coprescription of
controlled substances; therefore, decreasing the misuse and abuse of controlled substances
(NIDA, 2018).
A report published by the HHS has cited prescribing patterns of prescribers as a driving
force of the substance abuse epidemic.
The data indicates a small percentage of the providers are responsible for prescribing the
majority of the opioids and a small number of patients are responsible for consuming the
majority of the opioids; therefore, representing the greatest risk for overdose. (HHS, n.d.,
p. 15)
In response to the substance abuse epidemic, the PDMP has become the most promising
tool to assist in the reduction of the misuse and abuse of controlled substances. The PDMP is a
tool that can be used by providers to enhance clinic decision making and improve individual
safety while also helping curb the public health crisis of prescription drug misuse and
unintentional overdose deaths (SAMHSA, 2017). According to a study conducted by Reifler et
al. (2012), data from the poison control centers from 2003 to 2009 reported lower annual
increases in opioid misuse/abuse when using the PDMPs. According to the Prescription Drug
Monitoring Program Training and Technical Assistance Center, 13 states have mandated the use
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of the PDMP by prescribers and dispensers, 27 have mandated prescribers only, and two states
have no mandatory laws (PDMP, 2018).
According to Jann et al. (2014), improving and enforcing legislation of existing laws are
needed to keep abreast of the compelling circumstances with substance abuse problems.
Education and improved medical practice in prescribing opioid analgesic and benzodiazepines
are necessary for all healthcare professionals and patients using evidence-based guidelines.
Therefore, all healthcare professionals need to monitor their patients closely.
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Chapter 2: Literature Search Methods
The search engines that were used consisted of PubMed, CINAHL, Medline, OVID,
PsychoInfo, and scholarly evidenced-based journals were used for literature research. Multiple
sites such as the CDC, Whitehouse.org, SAMHSA, Georgia Medical Board, and NIDA were
used for statistical data retrieval.
Literature Review Discussion
Nguyen et al. (2017) suggested healthcare providers’ care should be aimed at decreasing
unpleasant symptoms such as emotional stress, anxiety, fear, panic, and pain to achieve optimal
patient homeostasis and improve patient outcomes. Pain and anxiety usually co-occur. Lin and
colleague (2005) concluded patients with higher levels of anxiety often experience greater levels
of pain. According to Lin and Wang (2005), “pain is a unique and personal experience that
results from a dynamic interaction of multiple dimensions, including physiological, sensory,
affective, cognitive, behavioral, and sociocultural aspects” (p. 2).
Motl and McAuley performed a study in 2009 evaluating fatigue, depression, and pain as
predictors of physical activity in patients with multiple sclerosis utilizing the TOUS. The study
concluded
1) fatigue, depression, and pain represented a symptom cluster; 2) the symptom cluster
had a strong and negative predictive relationship with physical activity behavior; and 3)
functional limitations, but not self-efficacy, accounted for the predictive relationship
between the symptom cluster and physical activity behavior. (Motl & McAuley, 2009,
pp. 276–277)
In reviewing the American Chronic Pain Association Resource Guide to Chronic Pain Treatment
(ACPA, 2018), approximately 32 million people in the United States have reported pain for
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greater than one year. More than half of the patients who have complained of pain are depressed.
Approximately 65% who have reported being depressed have complained of pain. Pain is a
debilitating factor that can provoke an emotional response of increased depression and anxiety.
The depression that is felt may mimic “physical pain” (ACPA, 2016).
According to a study performed by Wilsey et al. (2008), patients with chronic pain who
present to the ED and urgent care facilities for opioid treatment have high rates of psychiatric
diagnoses and substance abuse. In this study, chronic pain is often associated with an affective
disorder (Wilsey et al., 2008). In addition, it was noted that there is “an association between both
psychiatric or psychological disorders and problem drug use with initiation and use of prescribed
opioids in the general population” (Wilsey et al., 2008, p. 1111). Wilsey et al. evaluated an
epidemiologic study that suggested depression, anxiety, and drug abuse disorders were also
associated with the increase in opioid abuse. The study results concluded “approximately 60% of
patients with chronic pain have two or more psychiatric or psychological diagnoses. Depression
was the most common comorbidity followed by anxiety” (Wilsey et al., 2008, p. 1112).
Jones and McAninch (2015) suggested widespread co-use of benzodiazepines and
opioids is commonplace. Jones and McAninch (2015) reviewed a study on opioid naïve patients.
The study results concluded “benzodiazepine use was a stronger predictor of future opioid use
than was musculoskeletal pain. Among patients who abuse opioids, benzodiazepine abuse is
prevalent also, and co-users report using benzodiazepines to enhance opioid intoxication” (Jones
& McAninch, 2015, p. 494). These are the behaviors that lead to polypharmacy (taking more
medication than needed), patient’s doctor shopping (trying to get prescriptions to maintain their
addiction), and pharmacy shopping (using multiple pharmacies to fill prescriptions and hide their
addiction). The co-use of benzodiazepines and opioids can produce a synergizing effect causing
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drowsiness, a decrease in respiration, and a sense of euphoria resulting in death (Jones &
McAninch, 2015). Thus, the literature review suggests the use of the Prescription Monitoring
Program (PMP) used concomitantly with education on nonpharmacological interventions to
safely care for patients (Jann et al., 2014). The PDMP is a website that collects and lists all
controlled substances prescribed to a patient, the date prescribed, the date filled, the pharmacy
that filled the prescription, the name and address of the prescriber, and the quantity of the drug
including any available refills (Jann et al., 2014). In addition, it “can enhance the clinical
decision making process and improve individual patient safety while also helping curb the public
health crisis of prescription drug misuse and intentional overdose deaths” (SAMHSA, 2017, p.
1).
According to the Drug Abuse Warning Network (DAWN) and the National Vital
Statistics System, from 2004-2011, the number of ER visits regarding the rate of nonmedical use
involving both opioids and benzodiazepines has increased from 11 to 34.2 per 1000,000
population (Jones & McAninch, 2015). Concurrently, the number of opioid analgesics overdose
deaths involving benzodiazepines has increased yearly from 18% in 2004 to 31% in 2011 (Jones
& McAninch, 2015). Enhancing provider education, focus on strengthening coordination among
federal agencies, provider education programs, and continuing to develop and refine targeted
educational materials for different types of providers (HHS, n.d.), prevention strategies for the
use of prescription databases (PDMP) along with evidence-based guidelines (Jann et al., 2014)
will assist in reducing the misuse and abuse of prescription medications.
According to SAMHSA (2017), “Provider surveys, case studies, state evaluations, and
other reports offer growing evidence that individual state databases are reducing diversion while
also improving individual clinical decision making, prescribing practices, and lowering the rates
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of admission for substance abuse treatment” (p. 5). In a survey conducted by the Multnomah
County Health Department and Oregon Health Authority, the results of a provider survey on the
use of the PDMP from 675 health care providers were: about half (54%) were moderate or active
users, and using the system had generated the following activities for the majority of providers in
the past 30 days: spoken with a patient about controlled substance use (78%), confirmed patient
not misusing prescriptions (68%), confirmed patient was doctor shopping (59%), and/or reduced
or eliminated prescriptions for a patient (59%). There was also evidence that system use had led
to more communication between providers, other clinicians, and staff within their practice
(64%), other providers who write prescriptions (6%), other pharmacists (63%), and patients
(79%).
In a review of the effectiveness of PDMP, a research study conducted by Worley (2012),
concluded the PDMP reduced the incidence of doctor shopping, changed the prescribing
behaviors, and reduced prescription drug abuse. Brandeis University (the PDMP Training and
Technical Assistance Center) suggested in a 2014 briefing, the PDMPs were effective in
improving clinical decision-making, reduced doctor shopping and diversion of controlled
substances, and assisted in other effects to reduce the prescription drug abuse epidemic. In a
study conducted by the University of Kentucky Institute for Pharmaceutical Outcomes and
Policy (2015), concluded that mandatory provider and dispenser enrollment in Kentucky’s
PDMP program resulted in closures of nonphysician-owned pain management facilities and a
reported 50% reduction in the rate of individuals that doctor shopped.
The final literature review conducted concluded a significant reduction in opioid-related
overdose deaths. In this study, Hefei and his colleagues (2017) determined states with the PDMP
mandates were associated with a nine to 10% reduction in population-adjusted numbers of
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Schedule II opioid prescriptions received by Medicaid participants and similar reductions in
Medicaid spending on these prescriptions.
It is evident that the PDMPs are assisting providers in providing a better quality of care
while reducing the incidence of misuse and abuse of prescription drugs. However, its
effectiveness is based on the provider’s compliance with the use of government regulations as
part of the standards of care when prescribing controlled substances. Although the morbidity and
mortality rates involving opioids may be increasing, the evidence has shown rates of increase has
slowed in states that have implemented the PDMP versus the states that have chosen not to
implement the program (Congressional Research Service Report, 2018).
According to the Congressional Research Service Report (2018, p. 8), the PDMP is a
state-wide program that entails:
1. Hardware such as servers.
2. Software to run the PDMP database and ensure information security.
3. Connectivity such that pharmacies and dispensaries can enter data, and prescribers and
/or law enforcement officials can request and access data:
a. Staff to administer the PDMP and provide technical assistance; and
b. overhead fees.
The cost to start up and operate such a program involves financing from the state’s general fund,
prescriber and pharmacy licensing fees, state-controlled substance registration fees, health
insurer’s fees, direct-support organizations, or via state and/or federal grants (National
Legislation & Implementation Meeting, 2010). There are guidelines on how the PDMPs are
funded. These guidelines are given to each state and are outlined in the state’s PDMP authorizing
legislation (Congressional Research Service Report, 2018).

20
According to the Congressional Research Service Report (2018), as of February 2018, 50
states, the District of Columbia and two territories (Guam and Puerto Rico) had operational
PDMPs within their borders. The costs of the PDMP varies with startup cost ranging from
$450,000 to over $1.5 million and with the annual costs ranging from $125,000 to nearly $1.0
million (Congressional Research Service Report, 2018). The PDMP is also supported via the
federal government through programs such as, a grant called the Harold Rogers Prescription
Drug Monitoring Program incorporated into the new Comprehensive Opioid Abuse Program
sponsored by the Departments of Justice (DOJ) and the National All Schedules Prescription
Electronic Reporting (NASPER) sponsored by the Health and Human Services (HHS), State
Demonstration Grants for Comprehensive Opioid Abuse Response, Opioid Prevention in States
grants, State Targeted Response to the Opioid Crisis Grants, and various pilots and initiatives
under the Office of the National Coordinator for Health Information Technology (ONC;
Congressional Research Service, 2018).
Although some states had given assistance with funding via the federal government and
supporting agencies, some states prohibited the utilization of the funds (Congressional Research
Service, 2018). Thus, hindering the efforts and strategies set forth by the Office of National Drug
Control Policy (ONDCP). The ONDCP is a national program responsible for creating policies
aimed at reducing the use, manufacturing, and trafficking of illicit drugs and the reduction of
drug-related crime and violence and of drug-related health consequences (GAO, 2019).
Opioid-related deaths are now considered to be the leading cause of injury deaths. In the
United States, it surpasses deaths caused by suicides, gunshot wounds, and motor vehicle
accidents. According to Stein et al. (2017), the opioid-related emergency department visits more
than doubled, rising from 22 per 100,000 to 55 per 100,000 in 2011. The emergency room visits
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in 2011 related to the nonmedical use of pharmaceuticals and pain relievers were greater than
1.24 million (Stein et al., 2017). The data also indicated Medicaid-enrollees with a history of
OUD accounted for 45% of opioid analgesic prescriptions filled, 37% filled benzodiazepines,
and 21% filled both within a year of their diagnosis (Stein et al., 2017).
“The annual societal costs of opioid abuse, including overdose deaths, lost productivity,
criminal justice costs, and individual health care costs is an estimated $55.7 billion” (Stein et al.,
2017, p. 1). In an article written by LaPointe (2019), the opioid overdose care totals $1.94 billion
in annual hospital costs between October 2018 and October 2019. The opioid overdose patients
were found to would add about $11.3 billion to the United States (U.S.) healthcare system based
on current hospital costs data. In reviewing these cases, it was determined that 66% of the
overdose patients were insured via Medicaid and Medicare equally. Thus, leaving Medicaid and
Medicare to pay for expenses estimated at $7.4 billion (LaPointe, 2019).
In a study conducted by Stein et al. (2017), indicated prescribing opioid analgesics and
benzodiazepines to individuals diagnosed w/Opioid Use Disorder (OUD) can increase the risk
for medical consequences, relapse, and overdose. Stein et al. (2017) also indicated influences on
prescribing practices and medication choices are not limited to physicians in the same practice.
These so-called influences can be seen in the practices of other physicians in which patients have
been referred. Patients with diagnoses of mental health and physical ailments have ranked the
highest in coprescriptions of opioids and benzodiazepines. Stein et al. (2017) concluded the
incidence of multiple providers treating patients with OUD need to develop interprofessional
collaborations.
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In a review of the 2017 Executive Summary, “The Opioid Epidemic from Evidence to
Impact,” written by Alexander et al. consisted of the following five areas as ways to assist in the
reduction of the opioid crisis.
1. Prescription drug monitoring programs, state-level programs governing the use of
controlled substance prescribing information for providers, law enforcement and other
stakeholders.
2. Clinical guidelines that synthesize information regarding the safety, effectiveness and
risk-benefit balance of prescription opioids in different clinical settings.
3. Pharmacy benefits managers and pharmacies, two essential stakeholders in the supply
chain whose policies and procedures can reduce unsafe opioid use.
4. Engineering strategies, such as innovative packaging solutions that can reduce nonmedical opioid use as well as diversion.
5. Patient and public engagement, such as coordinated, community-based initiatives to raise
awareness and facilitate action alongside other interventions that address the broader
context in which the epidemic is occurring. (p. 14)
Alexander et al. (2017) made strong recommendations to establish general guidelines for
caring for patients with pain management issues. In their report, references were made toward
reeducating providers on the opioid crisis concerning writing prescriptions. The report also
reminded providers that opioids are not the first line of treatment for chronic non-cancer pain
management. Suggestions were made to educate the patients on the opioid epidemic, the risks
and benefits of the long term use of opioids, alternative treatments both pharmacological
(acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs], select anti-depressants, muscle
relaxants, select anticonvulsants, and topical analgesics) and nonpharmacological (physical

23
therapy, therapeutic massage, acupuncture, biofeedback, yoga, and heat or cold therapies), and
educate the community on the resources available to the population in need (Alexander et al.,
2017).
Upon completing an extensive literature review, it can be determined; the PDMP is a tool
that helps to combat the overprescribing of opioids and the concomitant prescribing of controlled
substances contributing to the misuse and abuse of controlled substances (Alexander et al.,
2017). The PDMP has proven to be beneficial to the patients and all parties involved in their
care. The literature does not give a specific monetary benefit of the use of the PDMP because as
aforementioned, it is a state ran program, and the regulations vary depending on laws within that
state.
In reviewing the adverse effects caused by the misuse and abuse of controlled substances,
it is safe to deduce the financial gain from the use of the PDMP would present as follows:
1. a decrease in the number of emergency room visits per year related to opioid abuse and
misuse,
2. a reduction in the number of hospital admissions for medical conditions resulting from
opioid abuse and misuse,
3. a reduction in violent crime and criminal arrests involving the misuse and abuse of
opioids,
4. a reduction in the need for law enforcement services related to drug trafficking due to the
misuse and abuse of opioids, (Alexander et al., 2017, p. 13), and
5. a reduction in the medical coverage premiums due to a decrease in the number of opioid
abuse cases (LaPointe, 2019).
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Despite the launching of the PDMP in efforts to combat substance abuse and study results
reporting physicians decreasing the number of opioid prescriptions written, the usefulness of the
PDMP, and a decrease in opioid-related deaths (Alexander et al., 2017), all parties are still not
onboard in the fight against the opioid epidemic. As aforementioned, as of current, 49 states
excluding Missouri is participating in the PDMP program (Davis, 2018). The fight against the
opioid epidemic cannot be successful without total participation in the efforts being set forth.
Thus, assisting in the continuance of the soaring rates reported within this opioid crisis.
Theoretical Framework Discussion
The middle-range theory of unpleasant symptoms created by Lenz et al. (1997), is used to
describe the relationship between opioid and benzodiazepine misuse and abuse. In this theory
(Figure 1), there are three significant components: influence, interaction, and feedback (Myers,
2009). Lenz et al. (1997) have concluded “the symptom a patient experiences is due to
situational, psychological, and physiological factors. The influencing factors give rise to or affect
the nature of the symptom experience and the consequences of the symptom experience” (p. 14).
The middle-range theory of unpleasant symptoms is a biofeedback theory which allows for one
or more symptoms to exacerbate effects on performance as well as to provide a reciprocal
influence on the physiologic, psychological, and situational factors (Myers, 2009).
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Figure 1
Updated Version of the Middle Range Theory of Unpleasant Symptoms

Note. From “The Middle-Range Theory of Unpleasant Symptoms: An Update,” by E. R. Lenz,
L. C. Pugh, R. A. Milligan, A. Gift, & F. Suppe. 1997, Advances in Nursing Science, 19(3), pp.
14–27. Copyright 1997 by Wolters Kluwer Health. Reprinted with permission.
Chapter Summary
Prescription drug abuse is a serious health issue that affects all healthcare providers
nationally. Addressing this epidemic is not the job of one person but a collaborative effect of all
healthcare disciplines. Ultimately, the reduction of the misuse and abuse of opioids will depend
upon continual provider education, focus on strengthening collaboration among federal agencies,
and prevention strategies for the use of prescription databases (PDMP) along with evidencebased guidelines (HHS, n.d). In addition to PDMP, it is important to provide patient education.
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Providers must be available to address patient concerns and offer alternative evidence-based
treatments such as, administering non-controlled anxiolytics, teach valuable coping mechanisms,
and relaxation techniques involving imagery, massage, breathing, and music intervention (HHS,
2015). Nguyen et al. (2017) suggested that by managing pain and anxiety, healthcare providers
can help decrease the incidence of many common complications resulting in reduced recovery
time. Thus, according to Stein et al. (2017), individuals with substance abuse disorders are prone
to relapse due to a host of environmental, patient, and provider factors. Therefore, it is
recommended to use caution in prescribing opioid analgesics and benzodiazepines to individuals
with a history of opioid use disorder (Stein et al., 2017).
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Chapter 3: Research Method
Currently, the coprescription of benzodiazepines and opioids are being reported in such
high numbers; it is being declared an epidemic. The research is still ongoing and the data, which
is still being produced, indicates the continued misuse and abuse at alarming rates. In a study
conducted by Hernandez et al. (2018), reported an estimated 30% of fatal opioid-related
overdoses involved the concurrent use of benzodiazepines. The report also concluded:
1. concomitant opioid and benzodiazepine use were associated with a 3-fold increase in
the risk of fatal overdose,
2. that concurrent use was associated with 2.15 times greater odds of an emergency
department visit or inpatient admission for overdose,
3. during the first 90 days of concomitant benzodiazepine use, the risk of opioid-related
overdose is five times higher compared with opioid use alone, and
4. the numbers of opioid and benzodiazepine prescribers were associated with an
increased likelihood of concurrent opioid and benzodiazepine use and an increased
risk of overdose and were strong confounders in examining the association between
concomitant use and overdose (Hernandez et al., 2018).
Although recommendations against coprescription of benzodiazepines and opioids from
various entities such as the CDC, current use of opioids and benzodiazepines has increased by
more than 40% in the last 12 years (Hernandez et al., 2018). Therefore, prescribers must be
cognizant of their prescribing practices and the prescribing practices of their colleagues. Thus,
the use of the PDMP, a tool to assist prescribers in identifying such behaviors as the
coprescription of opioids and benzodiazepines and patient misuse or abuse of benzodiazepines
and opioids is imperative to help in combating the epidemic. As aforementioned, educating
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providers on the use of the PDMP along with evidence-based guidelines when treating patients
will result in quality care.
Project Design
The project was designed to provide education on the use of the Georgia Prescription
Drug Monitoring Program (PDMP) and evidenced guidelines to foster changes in treatment
practices resulting in a decrease in the number of coprescriptions involving opioids and
benzodiazepines. A qualitative and quantitative descriptive analysis will be utilized for data
collection.
Measurement Tool
The survey tool being utilized in this project is called “Early Assessment of the
Prescription Drug Monitoring Program: A Survey of Providers (2013)” (Appendix D). The
survey tool originated from a survey performed in Oregon by the Multnomah County Health
Department and Oregon Health Authority to evaluate:
1. Methods for and experience with patient notification,
2. Feedback about program start-up and ongoing administration,
3. Perceived utility of the data system as a tool in patient care,
i.

Impact on:
o prescription behavior and approaches to pain management
o communication with other providers
o screening for potential misuse,

ii.

Perceived resource gaps,

iii.

Barriers for using the system more frequently, and

iv.

Suggestions for improvement (Orpdmp, 2013).
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The results of the survey tool are in direct alignment of the goal of conducting this project. The
results demonstrated improvement in the management of controlled substances (ORPDMP,
2013).
Reliability and Variability
According to Phelan and Wren (2006), reliability refers to the degree to which an
assessment tool produces stable and consistent results. In order to test-rest the reliability, one
must administer the same test twice over a period of time to a group of individuals. On the other
hand, validity, refers to how well a test measures what it is purported to measure (Phelan &
Wren, 2006).
In reference to this project’s data analysis process, reliability or validity testing was not
performed. The tool that was chosen, “Early Assessment of the Prescription Drug Monitoring
Program: A Survey of Providers” established in 2013 by the Program Design and Evaluation
Services at the Multnomah County Health Department and Oregon Health Authority previously
performed the initial reliability and validity testing.
Data Collection and Analysis
The data collection process was completely anonymous. The information collected did
not have any information identifying the participants. Confidentially of the data was maintained
and only accessible to the principal investigator, the statistician, ACU/IRB team, and project
committee members. Utilization of the 5-point Likert Scale (0 = Don’t know, 1 = Agree, -1 =
Disagree, 2 = Strongly agree, and -2 = Strongly disagree) and qualitative descriptive response
will also be used to use maintain confidentiality of the data. In addition, the participant was
identified alpha-numerically to ensure anonymity (e.g., physicians will be identified via P, Nurse
Practitioners via NP, and Physician Assistants via PA). The data were skewed in the order of
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receipt. Therefore, as more data were collected, the number of the identifier increases (e.g., P1,
P2, and P3).
Upon the completion of the survey and the data has been collected, the statistician
reviewed and formulated the statistical analysis utilizing a qualitative and quantitative
descriptive method needed to answer the PICOT question, For prescribers that coprescribe
benzodiazepines and opioids to the adult population (P) how does accessing the Prescription
Drug Monitoring Program (PDMP) prior to prescribing treatment (I) compared to not accessing
the PDMP when prescribing opioids and benzodiazepines (C) decrease the incidents of the
coprescribing of prescription medications (O) in a 3-month period (T)?
The data were analyzed to determine:
1. if the provider has accessed the PDMP, has the prescriber changed prescribing practices,
2. if the provider has accessed the PDMP, was there a challenge for the provider to provide
more patient education based upon the information obtained from the PDMP,
3. if the provider has accessed the PDMP, was there an increase in interprofessional
collaborative relations,
4. if the provider is accessing the PDMP, was the provider prompted to provide patient
referrals to higher levels of care, and
5. if the provider is not accessing the PDMP, was there need for reeducation.
The significance of this project was to educate providers and increase their use of the
PDMP in providing treatment. The recognition of the misuse and abuse of opioids and
benzodiazepines concurrently, indicate the need for a higher level of care and alternative
treatment options; therefore, assisting in the reduction in the mortality and overdose rate.
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Methodology
The project was conducted within a period of 3-months and was aimed at reeducating
providers about the PDMP and the coprescription of opioids and benzodiazepines in Mental
Health and Substance Abuse communities. The participants in this project will consist of 99
health care providers comprised of physicians, NPs, and PAs. These providers were randomly
selected from the community and that are affiliated with my current practice.
Upon Abilene Christian University IRB approval, a Lunch-n-Learn presentation was held
in the conference room. A presurvey was administered to evaluate the treatment practices of the
providers when providing treatment plans according to best evidence-based practices. A 60minute presentation was conducted explaining the significance of the pre- and postsurvey tool,
the length of the project study, reeducate providers on the current statistics regarding the opioid
crisis, the use of the PDMP, the benefits of incorporating the information from PDMP aimed at
providing the most current evidence-based treatments and ensure the highest quality of care was
provided.
At the end of the presentation, the participants were given instructions to mail the
completed postsurveys in the preposted and pre-addressed envelopes to the P.O. Box provided.
The participants were assured their identity and responses would remain anonymous, the data
collected and the jump drive would be secured via a double locked system, and placed in a safe
for 3 years. After the three-year expiration, the data collected would be shredded and the jump
drive erased.
The final phase of the project study consists of a follow-up. The participants were
notified a follow-up visit would be performed at the completion of the project to obtain provider
feedback on the ease of the project study and any recommendations towards further study
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practices. The participants were given the option to have access to the project results once the
project has been completed.
Findings
The findings were based on the hypothesis: for prescribers that coprescribe
benzodiazepines and opioids to the adult population, accessing the prescription drug monitoring
program (PDMP) and utilizing evidence-based guidelines before treatment will assist in the
reduction in the mortality and the coprescription rate.
Feasibility and Appropriateness
According to SAMHSA (2017), PDMPs considered to be increasingly valuable and an
easy-to-use resource for healthcare providers who prescribe and dispense controlled medication.
The utilization of the PMDP in conjunction the clinical decision-making process can assist in the
reduction of the misuse and diversion practices of controlled substances, lower the risk of
substance use disorders, and prevent opioid overdoses and deaths (SAMHSA, 2017). A brown
bag Lunch n’ Learn seminar was held in the conference room during lunch. The participates used
their personal computers to sign into the PDMP website. No materials or monies were required.
This project was not only appropriate for healthcare providers, but it was also an educational
seminar that enhanced their knowledge on how to protects their professional license, their
professional reputation, and their patients; all while providing good quality care.
IRB Approval and Process
The Institutional Review Board (IRB) is a group of individuals that have been formally
designated and charged with the task of reviewing and monitoring biomedical research involving
human subjects (FDA Guidance Documents, 1998). At some institutions, the IRB has an
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additional role, to take a second look at proposed scientific methods to ensure the highest quality
research (Enfield & Truwit, 2008).
According to Enfield and Truwit (2008), federal policy requires that an IRB have at least
five members: a chairperson, a scientific member, a nonscientific member, a lay person not
affiliated with the institution, and a practitioner. These members must be qualified through:
1. experience or expertise of its members,
2. must have diverse backgrounds,
3. may not be all of one profession, and
4. may not participate in the review of any project that might present as a conflict of interest
except to provide information (p. 1332).
The purpose of the IRB is to ensure that the appropriate steps are taken to protect the
rights and welfare of the human subjects participating in the research. Utilizing the guidelines set
by the FDA, the IRB performs independent reviews of research proposals and related materials
such as, informed consent documents, to determine whether they fulfill ethical standards (Enfield
& Truwit, 2008).
A signed informed consent document is [imperative] and evidence that the document has
been provided to a prospective subject (and presumably, explained) and that the subject
has agreed to participate in the research. IRB review of informed consent documents also
ensure that the institution has complied with applicable regulations. (FDA, 2008)
Therefore, the IRB has the authority to suspend or terminate any research project that violates or
is not in accordance with the federal guidelines (Enfield & Truwit, 2008).
“The role of the IRB is to safeguard human subjects by training researchers in research
ethics and best practices and reviewing research proposals” (Enfield & Truwit, 2008, p. 1333).
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Abilene Christian University requires all doctoral candidates to complete the following
competencies:
1. NIH/IRB Training (see Appendix H),
2. Human Subjects Research Protections (see Appendix I), and
3. Human Participation in Research (Ethic Course; see Appendix I).
Upon completion of the required core competencies, approval from the project chair and
the committee members, I was permitted to defend my project. Providing no revisions were
required, I was permitted to present my project to the IRB for review and to ascertain permission
to complete the intended project.
Once IRB approval was granted, I then moved into the data collection process. Utilizing a
statistician, I could then document the formal findings of the project. After completing the
intended project, the project chair and committee members reviewed the project to evaluate for
any FDA regulatory compliance or ethical violations. Providing there was no further changes
requested from the project chair and committee members, request to perform the final defense of
the DNP project was granted. At completion, the project chair and the committee performed their
final project review. If there were not any change requests and permission was granted, the
project was submitted for editorial review. It was at this point that all major changes were
completed according to editorial recommendations. Upon finalization of these changes, the
project was then prepared for publishing.
Interprofessional Collaboration
The PDMP is not a federally mandated program. The program is regulated independently
by the laws of the state participating in the program (SAMHSA, n.d.). According to the
Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP
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TTAC; n.d.), the program is operational in 49 states, the District of Columbia, and one U.S.
territory (Guam). Missouri is currently the only state that is not operational (SAMHSA, n.d.).
The PDMP entails data collected from nonhospital pharmacies and prescribers
(SAMHSA, n.d.). Prescribers or dispensers of any controlled dangerous substance (CDS)
prescription must report the written prescription within 24 to 72 hours including the following
information:
1. Type of drug dispensed,
2. Quantity of drug dispensed,
3. Number of days a given quantity is supposed to last (days’ supply),
4. Date dispensed,
5. Prescriber and pharmacy identifiers, and
6. Patient identifiers” (SAMHSA, 2017, p. 3).
As aforementioned, due to varying state laws, the various stakeholders that may have
access to the data within the PDMP are:
1. Prescribers
2. Dispensers
3. Law Enforcement
4. Regulatory Licensing Boards Researchers, and
5. Medical Examiners/Coroner Substance Abuse Treatment Providers Drug
Courts (SAMHSA, 2017, p. 3).
Thus, allying, especially between prescribers and pharmacist, aimed at reducing diversion,
misuse, abuse, and coprescription of controlled substances. Ultimately, this alliance will foster a
framework of checks and balances requiring interprofessional collaborations to ensure patients
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are appropriately filling their medication prescriptions, adhering to the current medication
treatment plan, and to provide the highest quality of care to patients.
Practice Setting
This project took place in various facilities within the community. The providers that
participated in this project specialized in treating the adult population with mental health and
substance abuse disabilities with comorbid pain. In this population, there was a trending
tendency to have cocurrent prescriptions for opioids and benzodiazepines. Thus, each provider
was asked to take a presurvey and postsurvey relating to the utilization or nonutilization of the
PDMP when diagnosing and treating patients changes their evidence-based treatment plan.
Informed consent was obtained from the owner of the facilities before any provider was asked to
participate in this study.
Target Population
The targeted population included 99 healthcare providers providing care to patients in the
community. The providers participating in this project had specialty training and provided
services to the adult population with a diagnosis of a mental health and/or substance abuse
disorder. The providers were located via the use of the local yellow pages and via colleague
referrals.
Risks and Benefits
According to Modizul and McRae (2014), provider risks are:
4. The chilling effect. Healthcare professionals may be reluctant to prescribe controlled
substances for fear of legal retribution. The chilling effect could also lead to increased
prescribing of alternate medications (substation effect), even if they are inferior in terms of
effectiveness or have greater side effects.
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5. Patient concerns about the refusal of a prescription for certain medications and
consequences. Healthcare providers worry about losing patient clientele because the
patient is not satisfied that he/she cannot access their medicine of choice. Patients who are
questioned about substance abuse and then denied an expect treatment, they become
angry, embarrassed, and cease the treatment, leaving the practice. Often, this results in
patients scrutinizing the practice and the healthcare provider. Most times the lack of
patient satisfaction results in adverse reporting of the practice and its providers; decreasing
revenue.
6. Wrongful categorization as fraudulent prescribers. Many healthcare providers do not have
sufficient knowledge enabling them to identify prescription abuse or signs of drug
diversion. As a result, the PDMPs may wrongfully suspect and categorized them as
fraudulent prescribers.
7. Breach of patient privacy. Healthcare providers are now collaborating with other health
care providers intermittently about certain patient cases. Healthcare providers feel that
medical consultation is no longer private.
8. The question of Law enforcement or healthcare? The abuse and misuse of prescription
medication has become such an epidemic; healthcare providers are comparing the PDMP
as a tool to police rather than a component of safety.
9. Mandatory use of the PDMP, time demands, and patient satisfaction. The PDMP requires
more time out of an already stressful day. As a lack of training, time constraints, and
general unfamiliarity of the database becomes a barrier (Mospan, n.d.), healthcare
providers opt not to prescribe controlled substances. This again leads to patient
dissatisfaction, poor survey ratings, lack of physician reimbursement and job security. (pp.
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2–3)
According to SAMHSA (2017), healthcare prescribers’ benefits are:
1. Identifying patients with risky substance use behaviors and refer them to treatment,
2. Educate patient not to share medication prescribed to them, and
3. Promote proper storage and disposal of prescription medications. (p. 8)
Timeline
The implementation of this project began at the beginning of the DNP program, January
2017 and will terminate at the completion of the program, May 2021. The sequence of events for
this project are depicted in Table 1. The actual research and data collection process occurred
within a span of three-months and has been incorporated within the timeline below.
Table 1
DNP Project Timeline and Task List
Date
January (2017)

February (2017)

May (2017)

June (2017)

Task
- Secured a doctoral prepared mentor
- Emailed mentor form to the DNP program
director
- Began formulating the project PICO
question
- Performed PICO presentation & peer
review to test for proper
structure
- Identified the project theoretical
framework
- Reviewed prospective project chair
biographies
- Began writing a problem statement and
designing the PICOT question with
mentor
- Began the literary review process
- Reviewed the DNP project guidelines
- Finalized the theoretical framework
- Finalized the PICOT statement
- Completed the ORSP training class
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Date
August (2017)
January (2018)

March (2018)
April (2018)

May – June (2018)
July (2018)
August (2018)
September (2018) – January (2019)
February – June (2019)
June -July (2019)

August- July (2020)
August (2020) – June (2021)

Task
- Completed the NIH IRB training courses
- Began writing Chap. 1 and 2
- DNP handbook acknowledgement r/t DNP
project
- Secured project chair and committee
- First meeting with project chair to discuss
research
- Presented project chair with the PICOT
research question, Chap. 1
and Chap. 2
- Secured permission to use survey tool
- Chap. 1-3 revisions
- Defense PowerPoint and revision
- Project chair grants permission to send
defense PowerPoint and
Chap. 1-3 to committee for review
- Chap. 1-3 revisions
- Defense proposal presented
- Revisions Chap. 1-3
- Dr. Gibson, chairperson; approved the IRB
submission
- Revisions Chap. 1-3
- Project presentation
- Data collection
- Inactivated data collection
- Developed Chap. 4-5 and revisions

Chapter Summary
This project hopes to provide health care providers with the tools and education of
incorporating the PDMP with evidence-based guidelines to improve patient treatment, to have a
better understanding of the dangers of coprescribing benzodiazepines and opioids, the factors
that contribute to the overdose and increase in mortality rates, increase their knowledge base
regarding the purpose and benefits of the prescription monitoring program, and recognize
alternative treatments for patients instead of coprescribing opioids and benzodiazepines.
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Chapter 4: Findings
The PDMP is a valuable tool that was developed to assist providers and pharmacists to
recognize patterns of over prescribing, educate patients about addictive behaviors, lower the rate
of misuse and abuse of controlled substances via modification of their own prescribing practices,
and increase patient safety. Utilization of the PDMP when prescribing control substance allows
the provider to ensure patients are not receiving multiple control substance prescriptions with
sedative affects (e.g., opioids and benzodiazepines) which increase the risk overdose and death
when used concomitantly with an opioid. Upon identification of any addictive behaviors,
providers can initiate conversations with the patients about possible medication misuse, provide
information on substance abuse treatment, and refer them for substance abuse screening and
counseling (SAMHSA, 2017).
Project Analysis
As aforementioned, the purpose of this project was to provide education to health care
providers on the ease of utilizing the PDMP, to bring awareness to the current initiatives
surrounding the opioid crisis, to improve the understanding and the dangers of concurrent
prescription drug abuse activities, to identify treatment plans to ensure the safe use of
prescription drugs having the potential for abuse, and alternative treatments for prescription drug
dependence (HHS, n.d.).
Discussion of Demographics
The project was to have been composed of 99 health care providers comprised of
physicians, NPs, and PAs. These providers were randomly selected from the community and
affiliates from my current practice. In review of the provider participation status for the survey,
please the survey overview below (see Figure 2).
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Figure 2
Survey Overview

Note. Twenty-two participants viewed. Six participants started and completed. Zero dropouts.
Data Analysis
The Likert scale, developed by Likert in 1932, was developed on the principle of
measuring people’s attitude by asking a serious of questions about a specific topic and measuring
their responses (Likert, 1932). The Likert scale has many varied responses and are ranked from
least to most (Allen & Seaman, 2007). Examples of such responses are:
1. Agreement: strongly agree to strongly disagree,
2. Frequency: Very Frequently to Never,
3. Importance: Very Important to Unimportant, and
4. Likelihood: Almost Always True to Almost Never True. (McLeod, 2008, pp. 1–2)
[Although], “in its final form, the Likert Scale is a five (or seven) point scale which is
used to allow the individual to express how much they agree or disagree with a particular
statement” (McLeod, 2008, p. 1); “scales are sometimes truncated to an even number of
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categories (typically four) to eliminate the neutral option to [requiring a] forced choice.”
(Allen & Seaman, 2007, p. 1)
According to Boone and Boone (2012), the Likert scale is composed of a series of four or
more Likert-type items and they must be combined into a single composite score/variable during
the data analysis to obtain a quantitative measure of a character or personality trait. Boone and
Boone (2012) further suggested to properly analyze Likert data, in the analysis process, the
Steven’s scale of measurement should be utilized. The Steven’s scale categorizes data into four
categories:
1. nominal scale – In this scale, observations are assigned to categories based on
equivalence and the numbers associated with the categories serve as only
labels (e.g., gender, eye color and race).
2. ordinal scale – In this scale, observations are ranked and measured by
magnitude. Here, the numbers only indicate order (e.g., letter grades, rankings,
and achievement [low, medium, high]),
3. interval scale – In this scale, the data use numbers to indicate order and reflect
meaningful relative distance between points on the scale. Interval scales do not
have an absolute zero (e.g., IQ test).
4. ratio scale – In this scale, the numbers indicate order and reflect a meaningful
relative distance between points on the scale and does not have an absolute
zero (e.g., age and years of experience; Boone & Boone, 2012).
The numbers that are attached to the data within the Likert scale depicts a relationship of
“greater than” and meets the requirement of the ordinal data scale. The data itself expresses
measurements via the mode or median for central tendency and frequencies for variability. Thus,
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descriptive statistics is recommended. The ordinal data can be further analyzed utilizing the chisquare measure (Boone & Boone, 2012). The chi square measure is used for testing relations
between categorical variables to prove their independence (McHugh, 2013).
Likert data can also be an analyzed via the interval measurement scale by calculating a
composite score (sum or mean). The descriptive statistics recommended for this scale would
include the mean for central tendency and standard deviations for variability. Data resulted from
the interval scale can also be further analyzed utilizing the Pearson’s r test. ANOVA, and
regression procedures to show variable correlations (Boone & Boone, 2012).
According to McLeod (2008), when analyzing the data from a Likert Scale:
1. Summarize the data using a median or a mode (not the mean). The mode is probably the
most suitable for easy interpretation.
2. Display the distribution of the observation in a bar chart and not a histogram. A
histogram cannot be used because the data is not continuous. (p. 2)
According to Boone and Boone (2012), if the Likert questions are unique and stand-alone, then
they should be analyzed as Likert-type items. The survey data can be resulted using the
following statistical tools: modes, medians, and frequencies (Boone & Boone, 2012, p. 3). Thus,
below are the results from the project survey.
Question Guiding the Inquiry
As aforementioned, the PICOT question for this project was, For prescribers that
coprescribe benzodiazepines and opioids to the adult population how does accessing the
Prescription Drug Monitoring Program (PDMP) prior to prescribing treatment compared to not
accessing the PDMP when prescribing opioids and benzodiazepines decrease the incidents of the
misuse and abuse of prescription medications in a 3-month period? The survey tool, “Early
Assessment of the Prescription Drug Monitoring Program: A Survey of Providers (2013),” was
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used in this project. The following questions were extracted and analyzed to answer the previous
mentioned PICOT question (see Figures 3–44).
Figure 3
Knowledge of the PDMP
Q1. Do you have any knowledge of the Prescription Drug Monitoring Program (PDMP)?

Q2. Considering this program, and from your own knowledge of the program and its goals,
please indicate how much you agree or disagree with the following statements. *Please choose
one answer per statement.
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Figure 4
PDMP Management of Prescription-Controlled Substances
Q2a. This program is likely to improve management of patient prescription for controlled
substances.
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Figure 5
Registering and Accessing the PDMP
Q2b. Over time, I think most providers and pharmacists will be interested in registering to access
and use this data system.
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Figure 6
Communication Between Providers
Q2c. This program will likely increase communication between providers.

Figure 7
Impact of the PDMP
Q2d. This prescription monitoring program will not have much impact.
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Figure 8
Benefits Compared to the Drawbacks of the PDMP
Q3. In general (not just for you or your practice) - so far, how have the benefits of the PDMP
compared to the drawbacks?

Q4. In general (not just for you or your practice), how useful has the PDMP been so far? How
useful is the PDMP?
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Figure 9
Monitoring Patient’s-Controlled Substance Prescriptions
Q4a. . . . in helping clinicians and pharmacies to monitor patients’-controlled substance
prescriptions?
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Figure 10
Control Patient Doctor Shopping
Q4b. . . . in helping to control doctor shopping by patients seeking to access or abuse controlled
substances?
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Figure 11
Provider Communication
Q4c. . . . in helping providers consult with each other about possible prescription abuse by
patients?

Q5. Considering this program, and from your own knowledge of the program and its goals,
please indicate how much you agree or disagree with the following statements. *Please choose
one answer per statement.
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Figure 12
Management of Patient Prescriptions
Q5a. This program is likely to improve management of patient prescriptions for controlled
substances.
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Figure 13
Registering and Accessing the PDMP
Q5b. Over time, I think most providers and pharmacists will be interested in registering to access
and use this data system.
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Figure 14
Increase Provider Communication
Q5c. This program will likely increase communication between providers.

Figure 15
PDMP Impact
Q5d. This prescription monitoring program will not have much impact.
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Figure 16
Benefits and Drawbacks of the PDMP
Q6. In general (not just for you or your practice) - so far, how have the benefits of the PDMP
compared to the drawbacks?

Q.7 In general (not just for you or your practice), how useful has the PDMP been so far? How
useful is the PDMP?
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Figure 17
Monitoring Patient’s-Controlled Substance Prescriptions
Q7a. . . . in helping clinicians and pharmacies to monitor patients’-controlled substance
prescriptions?
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Figure 18
Control Doctor Shopping
Q7b. . . . in helping to control doctor shopping by patients seeking to access or abuse controlled
substances?
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Figure 19
Provider Consults
Q7c. . . . in helping providers consult with each other about possible prescription abuse by
patients?
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Figure 20
Use of the PDMP
Q9. How would you characterize your use of the PDMP system?

Figure 21
Ease of Patient Access
Q11. How easy has it been to access patient information?
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Figure 22
Asscessed Patients via PDMP
Q12. In the last 30 days, about how many separate patients have you accessed the PDMP to
monitor or check on prescription medication?
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Figure 23
Reasons for Accessing the PDMP
Q13. In the past 30 days, for which of the following reasons have you used the PDMP system?
*Please check all that apply.

Q14. Some providers have reasons for not using the PDMP system more often. How much do
each of the following barriers keep you from using the system more?
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Figure 24
Barriers for Not Using the PDMP

Figure 25
Internet Limiting PDMP Access
Q14. Limitations with internet access at work
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Figure 26
Limitations of Time
Q14b. Nor enough time

Figure 27
Nonbeneficial to Office
Q14c. Lack of benefit for my office
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Figure 28
Support Staff Has No Access
Q14d. Support staff not being allowed to access the system under my account

Figure 29
Lack of Training
Q14e. Lack of training on how to use the PDMP system.
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Figure 30
Difficulty Using PDMP
Q14f. The system is not easy to use.
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Figure 31
Actions Resulting From Utilization of the PDMP
Q15. In the past 30 days, which of the following actions have you taken as a result of using the
PDMP system to monitor prescription medications for your patients? *Please check all that
apply.

Q16. As a result of using the PDMP system, do you communicate more with any of the
following groups?
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Figure 32
Who Do You Communicate More?

Figure 33
Number of Clinicians in the Office
Q16a. Clinicians and staff inside my practice.

68
Figure 34
Providers Writing Prescriptions

Figure 35
Pharmacists
Q16c. Pharmacists
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Figure 36
Patients
Q16d. Patients

Figure 37
Topics Most Communicated On
Q17. About which of the following topics do you communicate more with any of these groups?
*Please check all that apply.
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Q18. How useful would any of the following categories be as additional resources on the PDMP
website? *Please check all that apply.
Figure 38
Additional Resources

Q18a. Guidelines around pain management.
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Figure 39
Guidelines Around Pain Management
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Q18b. Advice for seeing patients with mental health and substance abuse issues.
Figure 40
Advice for Patients With Mental Health and Substance Abuse Disorders

Q18c. Recommendations for seeing patients with substance abuse problems.
Figure 41
Recommendations for Seeing Patients With Mental Health and Substance Abuse Disorders
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Q18d. Advice for seeing patients dually diagnosed with mental health and substance abuse issues
Figure 42
Patients With Dual Mental Health and Substance Abuse Disorders

Q18e. Making referrals for substance treatment.
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Figure 43
Referrals for Substance Abuse

Q18f. Interacting with patients using PDMP data.
Figure 44
Patient Interaction
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Data Analysis Summary
Upon reviewing the data collected, 100% of the participants admitted to having had
knowledge of the PDMP. In terms of the likelihood of the PDMP improving the management of
controlled substances, 50% of the participants agreed there would be some improvement
whereas, 50% of the participants disagreed. Yet, 70% of the participants agreed providers and
pharmacists would be interested in registering, accessing, and using the PDMP. Fifty percent of
the participants felt that the use of the data system would increase communication between
providers. Eighty-five percent of the participants agreed its use would not impact providers’
patient management.
In terms of utilization, 100% of the participants agreed in the use of the PDMP and
concluded its benefits outweighed its drawback. They also agreed the PDMP would help
providers and pharmacists to monitor the patients’-controlled substance prescriptions. Fiftyseven percent agreed the PDMP would help to control doctor shopping by patients seeking to
access or abuse controlled substances and 42% somewhat agreed. Eighty-five percent considered
the PDMP very useful in helping providers consult with each other about possible prescription
abuse.
The goals of the PDMP are to identify, educate, provide resources, and prevent drug
diversion (SAMHSA, 2017). Based on these goals, 57% of the participants agree the program is
likely to improve management of patient prescriptions for controlled substances. One-hundred
percent of the participants agreed most providers and pharmacists will be interested in registering
to access and use this data system. Again, the participants were divided on the ability of its use to
increase communication between providers. Fifty-seven percent agreed its utilization would
increase communication and approximately 43% disagreed. Fifty-seven percent of the
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participants also felt the prescription monitoring program will not have much impact and
approximately 43% of the participants disagreed.
In general, approximately 83% of the participants agreed the benefits of the PDMP
exceeded its drawbacks. Fifty-seven percent agreed the PDMP would help clinicians and
pharmacists to monitor patient’s-controlled substance prescriptions and 47% agreed that it would
somewhat help. In terms of the PDMP helping to control doctor shopping by patients seeking to
access or abuse controlled substances, 57% of the participants agreed and approximately 43%
deemed it would somewhat help.
The participants in this survey were providers who are registered to access the PDMP
database. Approximately 86% of the participants have utilized the database for more than two
months. Fifty-seven percent of the participants were recorded as moderate users and
approximately 43% were active or regular users. In evaluating the ease of the use of the PDMP,
the participants found the database very easy to use, easy to access patient information, and did
not experience any limitations in accessing the database.
In utilizing the PDMP, the participants reported an increase in patient education related to
controlled substance use, confirmation of patients not misusing prescriptions, confirmation of
patients’ doctor shopping, reduction or elimination of prescriptions for patients, and referrals to
other resources. Such resources include: pain management, substance abuse, and anxiety
management. As a result of the PDMP utilization, the participants not only reported an increase
of communication between providers, medical staff, pharmacies and patients, but, found
themselves consulting more about pain management, drug interactions, doctor shopping, and
substance abuse treatment. The participants also gave recommendation for additional resources
to be available on the site during treatment. Such resources were to include guidelines around
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pain management, advice for seeing patients with mental health and substance abuse issues,
recommendations for seeing patients with substance abuse problems, advice for seeing patients
dually diagnosed with mental health and substance abuse issues, making referrals for substance
treatment, and interacting with patients using PDMP data.
Limitations of the Project
The survey results have shown that incorporating the PDMP in the clinical decisionmaking process, has led to a decrease in providers coprescribing opioids and benzodiazepines.
The incorporation of the PDMP and clinical decision-making has also led providers to modify
their treatment plans to include alternative treatments. Such as, therapy, meditation, and exercise.
Thus, aiding in lowering the threshold for patient misuse and abuse of opioids and
benzodiazepines, and the ability to doctor shop.
Although, the survey results have been in alignment with the current literature and the
recommended changes in the treatment plans for providers’ prescribing opioids and
benzodiazepines, there were limitations that may or may not have affected the survey findings.
The limitations that were founded in this project were:
1. The survey participation was limited. Thus, there was a small number of people
representing a larger population. There is the consideration that if there were more
participation, would the survey results still have consistent with the current literature.
2. Although the data were self-reported and anonymous, they may have been some
inaccuracy in answering the questions as to appear compliant or due to unknown selfbiases.
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Interpretation and Inference of the Findings
According to the data obtained and analyzed, the PDMP is a beneficial tool that assists
providers in their prescribing practices. The database was shown not be difficult to access, there
were no limitations preventing registration or utilization, the benefit of the PDMP out ways the
risks, it helped to monitor controlled substances, its use, and doctor shopping, and helped to
improve communication with staff, providers, and pharmacists. In review of the goals and
management of patient substance use, providers are not convinced the PDMP will improve the
management of patient substance use, will not have an impact on the patient management, and
will not increase communication between providers regarding management of controlled
substance use.
Although, the results of the data analysis obtained for this project was inconclusive due to
having too small of a sample population, the lack of participation, the data were based solely on
the pretest survey, and insufficient data obtained for comparison, its findings were supported in a
report released by the American Medical Association (AMA). The AMA Opioid Task Force
released a report depicting an increase in the fatalities involving illicit opioids despite a reduction
in opioid prescribing and an increase use of the state prescription drug monitoring program
(AMA, 2020). Mann (2017) explained this phenomenon as a result of health care workers are
actually writing prescriptions for more opioid pills because of time constraints, that is because
government regulations have made prescribing more complicated and time-consuming. Thus,
giving validity to this project’s PICO question, How does accessing the Prescription Drug
Monitoring Program (PDMP) prior to prescribing treatment compared to not accessing the
PDMP when prescribing opioids and benzodiazepines decrease the incidents of the coprescribing
of prescription medications?
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According to the CDC (2020a), the clinical guidelines supporting the utilization of the
PDMP to access a patient’s history of controlled substance use prior to prescribing, allows
providers to improve the way [controlled substances] are prescribed, causes a reduction in the
number of people who misuse, abuse, or overdose from them, while making sure patients have
access to safe, effective management. Yet, over the past few decades, the cultural shift of
medicine and doctors’ over dependence on opioids to manage chronic pain has contributed to the
opioid epidemic (Gorman & Gorman, 2018). The misconception that “all pain is treatable has led
to the expectation that a patient experiencing more than mild discomfort should be treated with
pills and that the goal is to be completely pain -free” (Gorman & Gorman, 2018, p. 1). Thus, the
theoretical framework, the middle-range theory of unpleasant symptoms (TOUS) is extremely
important in the provider’s prescribing practices.
The TOUS is a biofeedback theory which allows for one or more symptoms to exacerbate
effects on performance as well as to provide a reciprocal influence on the physiologic,
psychological, and situational factors (Myers, 2009). In this theory, any alterations in symptom
quality, intensity, timing, and distress via physiologic, situational, or psychological factors will
alter patient outcomes (Nguyen et al., 2017). As aforementioned, it is imperative for healthcare
providers to understand and “consider factors that might influence more than one symptom and
the ways in which symptoms interact with each other” (Lenz et al., 1997) in order guide and
improve the decision-making processes and to provide better evidenced-based care.
The Harvard Medical School illustrates a great example of the TOUS. Pain, a symptom
most often felt, in the present of depression or anxiety makes treatment much more difficult.
People suffering from depression tend to experience more severe and longer lasting pain than
most people (Harvard Medical School, 2020).
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In many disease states, such as fibromyalgia, irritable bowel syndrome, lower back pain,
headaches, and nerve pain, symptoms of anxiety, depression, and pain, have a tendency to
overlap. Often, these patients are referred and may present with symptoms of psychological
distress. Approximately two-thirds of the symptoms of psychological stress has been attributed
to anxiety and 65% of the patient that seek help for depression have reported at least one type of
pain symptom. Therefore, psychiatric disorders not only contribute to the intensity of pain but to
the increased risk of disability. According to researchers, pain shares some of the same biological
mechanisms as anxiety and depression. Researchers have also found serotonin and
norepinephrine, two neurotransmitters that play a role in depression and anxiety, plays a role in
sending pain signals not only to the brain but the nervous system as well (Harvard Medical
School, 2020).
In treating patients where pain overlies anxiety and depression, treatment can be very
difficult and challenging (Harvard Medical School, 2020). For example, a patient with
fibromyalgia, a chronic disease, can cause chronic pain resulting in chronic depression.
Likewise, patients with major depression may feel physical pain (Harvard Medical School,
2020). Therefore, as previously stated, the utilization of TOUS should guide healthcare providers
to ask questions, such as “What is the symptom experience like for you?” (i.e., quality, intensity,
timing, and distress); “Are there other symptoms that occur when you are having this particular
symptom?”; “What contributes to making the symptom better or worse?” (i.e., physiological,
psychological, and situational factors); or “What effect does the symptom have on your everyday
life?” (i.e., performance; Nguyen et al., 2017, p. 5) when assessing patients. Upon analyzing the
factors that might influence more than one symptom and the ways in which symptoms interact
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with each other should assist in guiding and improving healthcare providers’ decision-making
processes to provide better evidenced-based care (Lenz et al., 1997).
Although a multitude of guidelines and various frameworks have been developed and
presented to the medical community to assist in rendering more evidenced based treatments,
healthcare providers continue to prescribe large quantities of [controlled substances]. Yet,
despite the research and warnings, healthcare providers are still aggressively prescribing opioids
knowing it’s not the safest or most effective treatment (Mann, 2017). Ultimately, focusing on
pain will mask both the clinician's and patient’s awareness that a psychiatric disorder is present
(Harvard Medical School, 2020).
According to the Harvard Medical School (2020), three treatment plans for patients
suffering from pain, anxiety, and depression are:
1. Double-duty psychotherapy. Double-duty psychotherapy consists of:
I.

Cognitive behavioral therapy (CBT). In CBT, the thoughts, feelings, and sensations are
all related. Therapists can utilize CBT to assist patients in learning to develop coping
skills. These coping skills with enable the patient to manage their pain instead of having a
feeling of victimization.

II.

Relaxation training. Patients can be taught techniques (progressive muscle relaxation,
yoga, and mindfulness training) to help relax and reduce their stress response. Stress can
exacerbate pain, anxiety, and depression.

III.

Hypnosis. Through hypnosis, the clinician can the patient with positive affirmations and
suggestions (e.g., the pain symptoms will improve).

IV.

Exercise. Regular exercise improves mood and decreases anxiety.
2. Double-duty medications. There are some medications that can be taken for pain and
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psychiatric conditions. The dual therapy is appropriate to reduce medication adverse
reactions. These medications include:
I.

Antidepressants. Selective serotonin reuptake inhibitors (SSROs), norepinephrine
reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs) are “double-duty drugs
that can treat both psychiatric disorders and pain” (Harvard Medical School, 2020). The
SNRIs such as Cymbalta, Effexor, have been used for diabetic neuropathy or
fibromyalgia. In addition, Effexor has been used for headaches. The TCAs such as Elavil,
nortriptyline, and desipramine have been used to treat nerve pain and chronic headaches.
In its lower doses it is effective to treat depression.

II.

Mood stabilizers. Mood stabilizers are anticonvulsants exert their effects by constraining
aberrant electrical activity and hyper-responsiveness in the brain (Harvard Medical
School, 2020). An example of such medication is Lyrica. Lyrica is used to treat diabetic
neuropathy, postherpetic neuralgia, fibromyalgia, and generalized anxiety disorder.
3. Combining psychotherapy and drugs. Combining psychotherapy and drug in patients
suffering from anxiety and depression will sometimes offer complete relief. In a study
“the Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP),” resulted
a combination therapy might work for people from pain and a diagnosis psychiatric
disorder (Harvard Medical School, 2020, p. 3).

Therefore, though an in-depth patient assessment and the utilization of the PDMP, healthcare
providers can reduce the use of opioids and benzodiazepines, reduce the risk of medication
misuse and abuse, lower addiction rates, and provide better evidence-base care.
The limitations in the participation of this project were due to the physician-nurse
conflict. Although the models of healthcare are changing to incorporate NPs into the arena where
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they are authorized to diagnose illnesses, treat conditions, and provide evidence-based health
education to their patients (AANP, 2020). The lack of knowledge of NPs scope-of-practice and
the traditional medical hierarchal model of practice, not only contributes to ineffective
teamwork, but results as a barrier to a successful collaboration. The traditional medical
hierarchal model promotes physician dominance over the healthcare team (AANP, 2020).
Dominance is defined as ruling, governing, or controlling; having or exerting authority or
supreme influence: dominant in the chain of command (www.dictionary.com, 2020).
In healthcare organizations, dominance is closely related to power and authority
especially in the decision-making process. Physician’s dominance has led to power
imbalance in health care organization and the failure of physicians to adopt and respect
the role of other health team members and the ethical role of other specialties especially
nursing. (Ameen, 2017, p. 2)
After presenting this project to the medical director, I was immediately challenged about
the content of the project regarding the utilization of the PDMP. The project tool was deemed
misleading and was thought to get providers to admit that they were not accessing the PDMP.
After reiterating the purpose of the project, requests were made to change the content of the
project tool, obtain approval to further complete the project at the desired location, and for the
project materials to be disseminated by a management. Allowing management to disseminate the
project tool to the participants would have greatly altered the project data as their answers would
not have been truthful for fear of penalization and void the promise of being anonymous. Upon
careful consideration, the requests of the medical director were declined. In return, the medical
director had a meeting with the rest of the management staff. The meeting resulted in this
investigator being transferred to another site, the EMR system used was restructured to include a
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prompt that ensured the PDMP had been accessed and if not, the provider was not able to
continue charting until the PDMP had been accessed when prescribing controlled substances,
and the dissemination of opioid and benzodiazepine overdose statistics in the faculties county
and the neighboring counties. Additionally, the data for this project had been forever lost.
Although, physician dominance plagued this project, it did bring awareness to the staff
regarding the importance of utilizing the PDMP in the clinical decision-making process. Yet, it
does not ensure the information gathered from the PDMP would be used to provide better
evidence- based care in a culture where systemically, the use of the PDMP was not initially
enforced. Research has shown many physicians regularly ignore federal guidelines, prescribing
large quantities of powerful opioid medications even when better treatment options are available.
Another possible cause is that physicians are aware of these policies, and they just choose not to
follow them.
Chapter Summary
Overall, the data shows that providers agree that registering for the PDMP was not
difficult, there were no limitations preventing registration or utilization, the benefit of the PDMP
out ways the risks, it helped to monitor controlled substances, its use, and doctor shopping, and
helped to improve communication with staff, providers, and pharmacists. In review of the goals
and management of patient substance use, providers are not convinced the PDMP will improve
the management of patient substance use, will not have an impact on the patient management,
and will not increase communication between providers regarding management of controlled
substance use.
Based on the data analysis, the information obtained in this study is inconclusive. The
inconclusively results from:
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1. Sample population- Ninety-nine providers were chosen for the study. Twenty-two
participants reviewed the measurement tool and only six providers participated. Thus, six
participants cannot effectively represent the thoughts of the community., and
2. Pretest and Posttest. The data obtained is based only on the pretesting phase.
The posttest was not preformed due to lack of adequate participation. Thus, there no data
available for comparison.
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Chapter 5: Discussion of Conclusions and Recommendations
According to the CDC (2017), in the past recent years, there has been a dramatic increase
in the acceptance and use of prescription opioids. Opioids which were used previously for the
treatment of moderate-to -severe pain following surgery, injury or health conditions such as
cancer, are now an accepted use for chronic pain, non-cancer related pain, such as back pain and
osteoarthritis, despite the serious risks and lack of evidence about their long-term effectiveness
(CDC, 2017). The CDC (2017) reports greater than 191 million opioid prescriptions dispensed to
Americans in various states in 2017. Alabama had the highest prescribing rate. Health care
providers wrote almost three times as many prescriptions per person as those in Hawaii (CDC,
2020a).
According to American Psychiatric Association (APA; 2017), addiction is a complex
condition, a brain disease that is manifested by compulsive substance use despite harmful
consequence. Often times, the drug addiction is so powerful that it encompasses their life
consuming all their time, and energy (APA, 2017). The CDC (2017), documents at least one in
four patients receiving long-term opioid therapy in primary care setting struggles with opioid
addiction. These opioid deaths often involve benzodiazepines (CDC, 2017).
Benzodiazepines are used for anxiety and sleep (Lembke et al., 2018). Medications, in
this class, are more effective when taken intermittently and no more than a month at a time.
When benzodiazepines are taken long-term, their effectiveness cease causing anxiety and
insomnia to worsen. According to Lembke et al. (2018), “In addition to addicion and death, longterm use of benzodiazepines can also contribute to cognitive decline, accidental injuries, and
falls” (p. 693).
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Lembke et al. (2018) reported a 67% increase (from 8.1 million to 13.5 million) in
benzodiazepine prescriptions from 1992-2013 and the overdose deaths involving
benzodiazepines have increase seven-fold between 1999- 2015. The risk of overdose death goes
up nearly fourfold when benzodiazepines are combined with opioids. Yet, the rates of
coprescribing benzodiazepines and opioids nearly doubled between 2001 and 2013 (Lembke et
al., 2018).
In an effort to reverse the opioid epidemic resulting from coprescribing opioids and
benzodiazepines, studies have recommended improving pain management guidelines and
offering patients alternative treatments for anxiety and insomnia. Such treatments consist of
behavioral intervention and long-term medications like selective serotonin reuptake inhibitors
(CDC, 2017; Lembke et al., 2018).
In review of the facts presented, the PICOT question, How does accessing the
Prescription Drug Monitoring Program (PDMP) prior to prescribing treatment compared to not
accessing the PDMP when prescribing opioids and benzodiazepines decrease the incidents of the
coprescribing of prescription medications in a 3-month period? was formulated, studied, and
analyzed.
Implications of Analysis for Leaders
Although there is a hierarchy between physicians and NPs, they perform their duties with
the similar goals. These goals include assessing patients, diagnosing patients, and treating
patients via evidence-based medicine to achieve better patient outcomes. Yet, some physicians
take it a step further, believing that NPs are incapable of providing quality, safe care at the same
level as physicians due to the lack of training (American Medical Association [AMA], 2010;
Fairman et al., 2011). Beliefs such as these, tend to keep many physicians practicing under the
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traditional medical hierarchal model of practice which promotes physician dominance over the
healthcare team (Hain & Fleck, 2014). Therefore, contributing to professional conflict and
hostility resulting from the “general perception that doctors are in charge, giving orders that both
nurses and patients must follow” (American Sentinel University [ASU], 2015, p. 1).
Nurse practitioners (NPs) are trained holistically. Nurses are taught to evaluate the body
as a whole. Nurses are taught to consider the emotional, social, and cultural factors that affect the
patient, whereas physicians are trained to focus on the patient’s symptoms, strategize treatments
and cures (ASU, 2015). The difference in education and practices between the two disciplines
can also cause conflict.
Physicians experience a great deal of pressure in practice. They are expected to focus on
seeing as many patients as possible, rather than the quality of care provided. In some facilities,
physicians are evaluated based on patient satisfaction scores. High patient scores may be able to
attributable to an increase in revenue. Therefore, in a culture where patient-centered satisfaction
is important, also is the risk for overprescribing various medications (Gorman & Gorman, 2018).
NPs experience a great deal of stress in practice as well. NPs not only face stressors in
regard to professional performance in the eye of the public, but they also face potential conflicts
ranging from physicians’ issues of competence to conflicts over diagnoses and treatment plans.
Although the role of the NP is steadily evolving and expanding, the fact remains in most states,
NPs are not independent practitioners and physicians ultimately make the final decisions in
treatment.
In reviewing the opioid crisis, it has been documented, physicians are not solely to blame
but do play a role in the continuance and the increase in misuse and abuse of controlled
substances due to their prescribing practices (Gorman & Gorman, 2018). A CDC study released
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in May of 2020, which found many physicians regularly ignore federal guidelines, prescribing
large quantities of powerful opioid medications even when better treatment options are available
(Mann, 2017). Providers that practice with a view of ‘all pain is treatable’ are practicing based on
the patient’s compliant and are treating patients according to their complaint and their clinical
judgement. Practice behaviors such as these are the cause of the increase of opioid and
benzodiazepine prescriptions (Gorman & Gorman, 2018).
In addition to the view that “all pain is treatable,” some physicians suffer from a
phenomenon called “small-area variation” in healthcare practice. In a study called the Dartmouth
Atlas of Healthcare project conducted in the 1920s, basically state doctors in similar social
networks make treatment decisions based on the habits and practices of those in their immediate
community. Thus, suggesting physician behaviors are not always govenened by evidence, best
practices, or guidlelines, but are greatly influenced by social signals (Gorman & Gorman, 2018).
In addition to the view that “all pain is treatable,” some physicians suffer from a
phenomenon called “small-area variation” in healthcare practice. In a study called the Dartmouth
Atlas of Healthcare project conducted in the 1920s, basically states doctors in similar social
networks make treatment decisions based on the habits and practices of those in their immediate
community. These studies suggest that physician behavior is therefore influenced by social
signals and not always governed by evidence, best practice, or guidelines (Gorman & Gorman,
2018).
NPs must always be cognizant of our practicing practices. Although we are not
independent practitioners, we must not fall into “small-area variation” practicing habits or feel
pressured into practicing in such a way that makes us uncomfortable or question our own ethics.
In these types of situations, “taking an intellectual approach instead of allowing one’s emotions
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to take control when confronted by conflicts with physicians is congruent with the concepts of
interprofessional collaboration” (Gegaris, 2007; Hain & Fleck, 2014). Interprofessional
collaboration can be utilized as a tool to broaden physicians’ knowledge about the role of a NP
and help to better strengthen relationships to achieve better practice (Hain & Fleck, 2014;
Maylone et al., 2011). Ultimately, physician-NP collaboration encompassing collegiality,
respect, and patient-centered care will result in better patient outcomes (Hain & Fleck, 2014).
The coprescription of opioids and benzodiazepines continue to increase due to patientcentered care, lack of time constraints, social networks, lack of provider knowledge related to
pain management, and in some cases, corporate’s unrealistic provider goals. Thus, this project
was performed within the framework of The Essentials of the Doctoral Education for Advanced
Practice Nursing (AACN, 2006) to provide implications for future practice.
EBP Findings and Relationship to DNP Essentials (I-VIII)
Essential I: Scientific Underpinnings
This project integrated the science of nursing incorporating the knowledge from ethics,
psychosocial, analytical, and organizational sciences as the basis for the highest level of nursing
practice (AACN, 2006). Evidence-based guidelines and protocols were utilized to reeducate
providers and implement changes in their prescribing practices of opioids and benzodiazepines
within the Mental Health and Substance Abuse communities. The education provided within this
project was bases on the theory of the middle-range theory of unpleasant symptoms (TOUS) and
the PDMP. Providers were tasked with utilizing the TOUS theory to assess a patient and
determine a treatment plan; then, access the PDMP to determine if their treatment plan would
remain constant. Ultimately, the goal was to recognize that there were alternative treatment plans
or resources for patients based on evidence-based guidelines than coprescribing opioids and
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benzodiazepines. Thus, limiting patient concomitant use of opioids and benzodiazepines,
reducing the possibility of misuse or abuse of these medications, and providing safer and higher
quality of care.
Essential II. Organizational and Systems Leadership for Quality Improvement and Systems
Thinking
The survey tool, “Early Assessment of the Prescription Drug Monitoring Program: A
Survey of Providers,” was used to assess the organization’s need for improvement of patient
safety and delivery of quality care via lowering controlled substance prescriptions. The
organizational and systems leadership for quality improvement and systems thinking were
accomplished via reeducating the healthcare providers about the opioid crisis, the dangers of
coprescribing opioid and benzodiazepines, and the use of the PDMP.
Essential III. Clinical Scholarship and Analytical Methods for Evidence-Based Practice
Researched the current literature relating to the opioid epidemic and the coprescription of
opioids and benzodiazepines. Utilized analytical methods to evaluate their results and
incorporated them into the educational presentation. Encourage healthcare providers to
implement these findings into their practice in hopes of promoting a safer and more effective
evidence-based approach when treating patients.
Essential IV. Information System/Technology for the Improvement and Transformation of
Health
Demonstrated the importance of accessing and evaluation of the information in the
PDMP database in the decision-making process. This information resulted in a request to resign
the EMR to incorporate a prompt to access the PDMP when prescribing a controlled substance.
If the provider did not access the PDMP when prescribing the controlled substance, the system
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alerted the provider that this quality control measure had not been fulfilled and wouldn’t be able
to be submitted for billing.
Essential V. Health Care Policy for Advocacy in Health Care
Performed a critical analysis of the health care policies at the local, state, and federal
level related to the opioid epidemic and its prescribing practices. Reeducated the healthcare
providers on such policies and issues related to patient-centered care surrounding the
overprescribing of opioids and the penalties associated with sentinel events resulting from not
accessing the PDMP.
Essential VI. Interprofessional Collaboration for Improving Patient Population and
Population Outcomes
Effective communication was employed between the Medical Director and the staff in
implementing this project. Although the project failed in terms of data collection. There was
evidence of culture change as the Medical director authorized the redesign of the EMR to include
access of the PDMP within the chart as a measure of quality improvement and in efforts to assist
in the reduction of coprescribing benzodiazepines and opioids to various patients. It was during
this point in the project, the reeducation of the NPs role was reiterated to foster change.
Essential VII. Clinical Prevention and Population Health for Improving the Nation’s Health
Analyzed the scientific data referencing the coprescription of benzodiazepines and the
misuse and abuse of opioids to implement change in provider prescription practices, improve
provider treatment plans to include alternative treatments. Thus, bridging the gaps in the
continuum of patient care.
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Essential VIII. Advanced Nursing Practice
An analysis was completed reviewing providers prescription practices, organization
needs for improvement to reduce the number prescriptions of opioids and benzodiazepines, the
population served, policies on coprescriptions at the state, government, and local levels.
Proposed changes in the clinical decision making, treatment plans of patients based on the
recommendations from various studies and guidelines set for by the supporting governmental
programs and certifying credentialing organizations and increase in provider communication
related to patients receiving opioids and benzodiazepines from multiple providers to increase
safer practices, provide better quality care based on the evidence-based guidelines.
Recommendations for Future Research and Clinical Practice
Due to the penalties associated with sentinel events associated with the overprescribing of
opioids and the high rates of co prescriptions, providers are not going to admit to not accessing
the PDMP. In order to address the opioid crisis and the problem of prescribers coprescribing
opioids and benzodiazepines concomitantly, providers should be required to obtain education in
pain management. Other, recommendations include: adding the PDMP prompt into the EMR’s as
a quality assure point and to making it easier for provider access, prepopulating controlled
substances at a lower dose or at tapering doses for patients who have pain doses that are not
controlled, offer therapy management option within the EMR, having a universal standard for
providers to communicate regarding patient controlled substance prescriptions, changing the
incentives and reimbursing more time with patients, the removal of pain as a score on
satisfaction surveys, and change the incentives provided by the pharmaceutical companies for the
use of their product (Gorman & Gorman, 2018). Of all the recommendations previously
mentioned, is an avenue for multiple studies needing to be performed in the intervention of the
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opioid epidemic and the coprescription of opioids and benzodiazepines. In order to elicit change
for the better, the root cause must be identified and resolved. Although, there are many barriers
to extinguishing this epidemic, it is also important to understand what providers think will make
it easier to access the PDMP, other than having ancillary staff print out reports, might be a great
place to start. Giving permission to ancillary staff to access the PDMP on the providers’ behalf
could be considered a breach of patient privacy.
Chapter Summary
This doctoral project was developed and performed with the expectation of providers
showing providers that the PDMP is a tool that helps in the decision-making process to lower the
coprescription of opioids and benzodiazepines, raise awareness to the outstanding numbers of
patients who doctor shop within our organization and the surrounding counties, and to raise
awareness of other medical treatments that are greatly underutilized and forfeited for pills as a
treatment option. The PDMP was not developed as a punitive measurement towards providers. It
is a tool that assists providers in their decision-making process to provide a safer and more
effective treatment plan that is based on proven evidence-based guidelines. Incorporating its use
into practice could lower the death rates.
Although, physicians are not solely to blame for the culture of overprescribing, they are
responsible for its continuum. As health care providers practice incorporates the patient-centered
care model, practitioners tend to prescribe what patients feel that want instead of what they need.
Prescribing what a patient may need, will not always place the provider in a positive light. Often
times, providers lose patients, revenue, and develop a less than stellar reputation because patients
cannot get what they want and tarnishes the providers reputation. Therefore, as a community of
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providers, interprofessional collaborative practice is imperative as providers have all sworn to
provide medical care based on ethics and with a duty to do no harm.
Ultimately, even if all the aforementioned changes were to have occurred, it does not
guarantee that healthcare providers will incorporate the information obtained from the PDMP in
the decision-making process for the betterment of patients. Thus, all we can do is try.
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Appendix B: Survey Tool Permission
M Gmail
Permission to use Survey Tool
Crystal Beddard <xxxxxxxx@xxxxxxxxx>
To: jxxxxxxxxx@xxxxxxxxx
Mon, Apr 23, 2018 at 12:22 PM
Dear Ms. Matson,
My name is Crystal Beddard and I am a Doctoral student at Abilene Christian University. I am
emailing you to ask for permission to use the survey in the Early Assessment of the Prescription
Drug Monitoring Program: A Survey of
Providers. I have attached a formal letter of request.
Thank you in advance for your help and support. If you have any questions, I can be reached via
cellphone at xxx-xxx-xxxx or via email at xxxxxxxxxx@gmail.com.
Sincerely,
Crystal Beddard
~ Letter-Seeking-Permission-to-Use-Survey.Questionnaire-Tool.Response-2.docx
29K

112
Appendix C: Permission Letter Response

Matson Jamie

<xxxxxxxxxxxx@xxxxxxxxxxxxxx>

Apr 23 (2
days ago)

To me
Hello Ms. Beddard,
Thank you for your patience. You have permission to use the Early Assessment of the
Prescription Drug Monitoring Program: A Survey of Providers survey/questionnaire instrument.
We’re interested in learning more about your project. Could you please send me a brief summary
about it?
Kind regards,
Jamie
Jamie Matson
Executive Specialist
Program Design and Evaluation Services
Oregon Health Authority – Public Health Division and
Multnomah County Health Department
xxxxxx xxxxxxxxxxxx xxxxxxx
Portland, OR 97232
xxx-xxx-xxxx
I/O: 125/B827/PDES
www.healthoregon.org/pdes

113
Appendix D: Survey Tool
PROGRAM DESIGN AND EVALUATION SERVICES
MULTNOMAH COUNTY HEALTH DEPARTMENT AND
OREGON HEALTH AUTHORITY
Early Assessment of the Prescription Drug Monitoring Program:
A Survey of Providers
January 10, 2013
Contact: David Dowler Phone: (xxx) xxx-xxxx
Fax: (xxx) xxx-xxxx
Email: xxxxxxxx@xxxxxxxx
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Appendix E: Survey Questions and Raw Frequencies
A. Results for TOTAL GROUP (N= ?)
1.

Have you heard about the Prescription Drug Monitoring Program, also known as PDMP?

? % of yes
? % no [please read summary below]
PDMP Summary:
This monitoring program became law and started up in September 2011. Pharmacies submit
prescription data to the PDMP system for all Schedules II, III and IV controlled substances
dispensed to Oregon residents. The protected health information (patient name, drug prescribed,
provider) is collected and stored securely. Oregon healthcare providers and pharmacists may
register for a free account to access information online from the PDMP system for their patients.
The program was started to help inform prescription practice.
? % This does sound familiar
? % I still don’t know what this is
2. Considering this program summary, and from your own knowledge of the program and its
goals, please indicate how much you agree or disagree with the following statements.
For each statement, please choose
one answer

Strongly
Disagree

Disagree

Agree Strongly
agree

Don’t
know

a. This program is likely to improve
management of patient prescriptions
for controlled substances.
b. Over time, I think most providers
and pharmacists
will be interested in registering to
access and use this data system.
c. This program will likely increase
communication between providers.
d. This prescription monitoring
program will not have much impact.
3. In general (not just for you or your practice) – so far, how have the benefits of the PDMP
compared to the drawbacks?
? % benefits exceed the drawbacks
? % benefits and drawbacks are about equal
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? % drawbacks exceed the benefits
? % I have no idea
4. In general (not just for you or your practice), how useful has the PDMP been so far?
How useful is the PDMP…

Very
useful

Somewhat
useful

Not useful

Don’t know

a …in helping clinicians and
pharmacies to monitor
patients ‟controlled substance
prescriptions?
b …in helping to control
“doctor shopping” by
patients
seeking to access or abuse
controlled substances?
c …in helping providers
consult with each other
about
possible prescription abuse
by patients?
Questions 2-4, for Registered Respondents Only (n=?)
2. Considering this program summary, and from your own knowledge of the program and its
goals, please indicate how much you agree or disagree with the following statements.
For each statement,
Strongly
please choose one
Disagree
answer
a. This program is
likely to improve
management of
patient
prescriptions for
controlled
substances.
b. Over time, I
think most providers and pharmacists
will be interested in
registering to access
and use this data
system.
c. This program
will likely increase

Disagree

Agree

Strongly
agree

Don’t know
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communication
between providers.
d. This prescription
monitoring
program will
not have much
impact.
3. In general (not just for you or your practice) – so far, how have the benefits of the PDMP
compared to the drawbacks?
? % benefits exceed the drawbacks
? % benefits and drawbacks are about equal
? % drawbacks exceed the benefits
? % I have no idea
4. In general (not just for you or your practice), how useful has the PDMP been so far?
How useful is the PDMP…

Very
useful

Somewhat useful

Not useful

Don’t know

a …in helping clinicians and
pharmacies to monitor
patients’ controlled
substance prescriptions?
b …in helping to control
“doctor shopping” by patients seeking to
access or abuse controlled
substances?
c …in helping providers
consult with each other
about possible prescription
abuse by patients?
B. Results for PHARMACISTS ONLY (N= ?)
5. Which of the following methods have you used to notify patients about the PDMP? (check all
that apply)
? % we have not been notifying patients
? % posters on the wall of the pharmacy*
? % printed PDMP information handed out with appropriate prescriptions
? % printed PDMP information handed out with ALL prescriptions
? % verbal notification to patients with appropriate prescriptions
? % verbal notification to all patients
? % something else [? comments]
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6. Have you heard about or received any complaints about the patient notification process from
patients?
? % no
? % yes
? % about how many separate complaints?
6a. What has been the primary complaint? (? comments)
7. Have you heard complaints from anyone other than patients about the patient notification
process?
? % no
? % yes, from pharmacy staff
? % yes, from health care providers?
% yes, from someone else
(please specify whom): (? comments)
8. Please think about your pharmacy’s experience participating in the Prescription Drug
Monitoring Program. Consider the statements below and indicate how much you agree or
disagree with each.
For each statement,Strongly
please choose Disagree
one answer
Disagree
a. Program
start up went
very
smoothly.
b. We had all
the
information
we needed
when the
program got
up and
running.
c. I wish
technical
support could
be more
helpful.
d. Overall,
this has been a
negative

Agre
e

Strongly agree

Don’t know
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experience for
our pharmacy.
e. Our current
experience
uploading
data is going
very well.
C. Results for Registered Pharmacists and Providers (N=?)
9. You have received this version of our survey because our records show that you have
registered online as a user, to request and access information on patients. Is this correct?
? % not correct, I have not registered for an account
? % not sure
? % correct
9a. For how long have you had an account?
? % 2 months or less
? % more than 2 months
? % not sure
10. How would you characterize your use of the PDMP system?
? % I have never used it
? % very minimal user
? % moderate user
? % active and regular user
Very easy

Somewhat
easy

Somewhat
difficult

Very Difficult

11. How easy
was it to
register as a
user?
12. How easy
has it been to
access patient
information?
13. In the last 30 days, about how many separate patients have you accessed the PDMP to
monitor or check on prescription medication?
? % none
? % 1 -5
? % 6 - 25
? % more than 25
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14. In the past 30 days, for which of the following reasons have you used the PDMP system
(check all that apply)
(PHARMACIST ONLY)(N=?)
? % to assess controlled substance use of new patients
? % to assess controlled substance use for patients who might be over-using
? % some other criteria (? comments)
(PROVIDER ONLY)(N=?)
? % when prescribing a controlled substance for a new patient
? % when prescribing a new controlled substance for an existing patient
? % when a patient requests an early refill on a controlled substance
? % to assess controlled substance use for patients who might be over-using
? % some other reason (? comments)
15. Some providers have reasons for not using the PDMP system more often. How much do
each of the following barriers keep you from using the system more?
Large
barrier

Medium
barrier

Small
barrier

Not a
barrier

a. Limitations with
internet access at work
b. Not enough time
c. Lack of benefit for my
office
d. Support staff not being
allowed to access the
system under my account
e. Lack of training on
how to use the PDMP
f. The system is not easy
to use
16. What else would you rate as a large or medium barrier keeping you from using the PDMP
system more often? (? Comments)

17. In the past 30 days, which of the following actions have you taken as a result of using the
PDMP system to monitor prescription medications for you patients? (check all that apply)
(PHARMACISTS ONLY)(N=?)
? % spoken with a patient about controlled substance use
? % contacted prescribers or other pharmacies
? % confirmed patient not misusing prescriptions
? % confirmed patient was doctor shopping
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? % denied prescription for a patient
? % something else (? comments)
(PROVIDERS ONLY)(N=?)
? % spoken with a patient about controlled substance use
? % contacted other providers or pharmacies
? % confirmed patient not misusing prescriptions
? % confirmed patient was doctor shopping
? % reduced or eliminated prescriptions for a patient
? % dismissed patient from practice
? % referred or recommended for substance abuse treatment
? % referred or recommended for pain management
? % referred or recommended for anxiety (or other psychiatric disorder)
management
? % something else (? comments)
18. As a result of using the PDMP system, do you communicate more with any of the following
groups?
Do you
communicate
more with…
a. Clinicians and
staff inside my
practice
b. Providers who
write prescriptions
c. Pharmacists
d. Patients

Yes,
definitely

Yes,
somewhat

No

19. About which of the following topics do you communicate more with any of these groups?
(check all that apply)
? % I don’t communicate
more
? % pain management

? % drug interactions
? % doctor shopping

? % substance abuse
treatment
? % something else

20. How useful would any of the following categories be as additional resources on the PDMP
website? (check all that apply)
Somewhat useful
V
Not useful
e
r
a. Guidelines around pain
y
management
u
b. Advice for dealing with
s
mental health issues
e
f
u
l
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c. Recommendations for seeing patients
with substance abuse problems
d. Advice for seeing patients
dually diagnosed with
mental health and
substance abuse issues
PROVIDERS ONLY
e. Making referrals for
substance abuse treatment
f. Interacting with patients
using PDMP data
e. Anything else (?
comments)
D. Results for Non Registered Pharmacists and Providers (N=306)
21. You have received this version of our survey because our records show that you have not
registered online as a user. Is this correct?
? % correct
? % not correct, I have registered for an account (pharmacists=? %;
providers=? %-- this a limitation)
22. Why haven’t you registered as a user? (choose all that apply)
(PHARMACISTS ONLY)
? % there is no internet access at work
? % I’m not aware that I could register as a user
? % I’m too busy
? % I don’t think there would be any benefits
? % I’m not allowed to share the account with my support staff
? % some other reason (please specify) (? comments)
(PROVIDERS ONLY)
? % there is no internet access at work
? % I’m not aware that I could register as a user
? % I’m too busy
? % I don’t think there would be any benefits
? % I’m not allowed to share the account with my support staff
? % I rarely, if ever, prescribe controlled substances
? % some other reason (please specify) (? comments)
Results for Total Group
23. What one thing would improve this program, if anything?
Registered Pharmacists:? (or ? %) made a comment
Registered Providers:? (or ? %) made a comment
Non-registered Pharmacists: ? (or ? %) made a comment
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Non-registered Providers: ? (or ? %) made a comment
24. What is your age?
? % under 30
? % 30-39
? % 40-49
? % 50-59
? % 60 or older
25. What is your gender?
? % male
? % female
26. What best characterizes your practice? (PROVIDERS ONLY)
? % large private office (6+ practitioners)
? % small private office (5 or fewer practitioners)
? % academic practice
? % emergency room
? % safety net clinic (e.g., FQHC)
? % hospital-based clinic
? % hospital: inpatient primarily
? % other
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Appendix F: MD Specialties Included and Excluded From Sample
Selection was made considering most likely specialties to be candidates for using the PDMP
MD Specialties included (n=?)
• Family, General,

MD Specialties excluded (n=?)
• Allergy, and Allergy and

•

Internal Medicine: ?

•

Emergency Medicine: ?

•

Obstetrics and Gynecology: ?

•

Orthopedic Surgery: ?

•

Anesthesiology

•

Psychiatry: ?

•

All surgeries specialties

•

Other selected specialties: ?

•

Child Neurology

•

Clinical Cardiac

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

acupuncture
addiction medicine
cardiovascular disease and cardiology
Child and Adolescent Psychiatry
Child Psychiatry
gastroenterology
geriatric medicine
gynecology
hospice and palliative care
occupational health
oncology
pain medicine
physical medicine and rehab
preventive medicine
psychosomatic medicine
public health and preventive medicine
pulmonary medicine
rheumatology
sleep medicine
sport medicine
therapeutic radiology
urology

Immunology
•

Anatomic Pathology and
Clinical Pathology

Electrophysiology
•

Critical Care Medicine

•

All pathology specialties

•

Dermatology

•

Diagnostic Radiology

•

Endocrinology, Diabetes and
Metabolism

•

Hematology

•

Infectious Diseases

•

Maternal and Fetal Medicine

•

Medical Genetics
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•

Medical Oncology

•

Neonatal-Perinatal Medicine

•

Nephrology

•

Neurology

•

Neuroradiology

•

Nuclear Medicine

•

Ophthalmology

•

Otology, Laryngology,
Rhinology

•

All pediatric specialties

•

Plastic Surgery

•

Radiation Oncology

•

Radiology

•

Vascular and Interventional

•

Radiology
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Appendix G: Site Permissions
Dr. Linda Gibson
Attn: IRB
Abilene Christian University
1600 Campus Ct.
Abilene, Texas 79601

Dear Dr. Gibson and IRB Members:
I have read over Crystal Beddard's proposal for her research project to be carried out at
XXXXXX XXXXXXX. I understand that this student is conducting this research project as part
of her requirements for the Doctor of Nursing Practice program at Abilene Christian University
in Abilene, Texas and will have the opportunity to present her research findings in other venues.
I understand that the Institutional Review Board for the Use of Human Subject's in Research
(IRB) at Abilene Christian University is concerned with protecting the confidentiality, privacy,
and well-being of research participants. Further, it is my understanding that the student will
additionally, be advised in this project by her Project Chair and the Project Committee members,
both of whom will have regular contact with this student.
I do not have concerns about the study the student has proposed based on conversations with the
student and after reviewing her research project proposal. The agency supports this student 's
plan and approves of the project, including recruitment of participant s and data collection,
through our agency.
Should you have additional questions or concerns, you may contact me Dr. XXXX XXXXXX at
xxx-xxx-xxxx or via email at xxxxx@xxxxxxxxxxxxxxxxxx.com

Sincerely,

Medical Director
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Appendix H: NIH/IRB Training Certificate
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Appendix I: Human Subjects Research Projections
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Appendix J: Online Research Ethics Course
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Appendix K: IRB Approval Letter

131
Appendix L: IRB Data Deactivation Letter
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Appendix M: Results of the Survey Tool (RAW Data)

Survey Overview

Viewed Started Completed
22

6

6

Completion
Rate
100%

Drop-Outs (After
Starting)
0

Average Time to Complete
Survey
10 minutes
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Q1. Have you heard about the Prescription Drug Monitoring Program, also known as
PDMP?

Answer

Count
6
0
6

1. Yes
2. No
Total
Confidence Interval @ 95% : Standard
Mean: 1.000
Standard Error: 0.000
[1.000 - 1.000]
Deviation: 0.000

Percent
100.00
0.00
100.00
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Q2. Considering this program, and from your own knowledge of the program and its goals,
please indicate how much you agree or disagree with the following statements. * Please
choose one answer per statement. (Overall Matrix scorecard)

***Overall Matrix Scorecard: 2. Considering this program, and from your own knowledge
of the program and its goals, please indicate how much you agree or disagree with the
following statements. * Please choose one answer per statement.
Question
1. a. This program is
likely to improve
management of
patient prescription
for controlled
substances.
2. b. Over time, I think
most providers and
pharmacists will be
interested in
registering to access
and use this data
system.
3. c. This program will
likely increase
communication
between providers.

Count
7

Score
2.286

7

2.429

7

2.429
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4. d. This prescription
monitoring program
will not have much
impact.

7

2.857

Average

2.500

***individual option analyzed:
Q2. a. This program is likely to improve management of patient prescription for controlled
substances.

Answer
1. Strongly Agree
2. Disagree
3. Agree
4. Strongly Disagree
5. Don’t know
Total
Confidence Interval @ 95% : Standard
Mean: 2.286
[1.357 - 3.214]
Deviation: 1.254

Count
3
0
3
1
0
7
Standard Error: 0.474

Percent
42.86
0.00
42.86
14.29
0.00
100.00
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Q2. b. Over time, I think most providers and pharmacists will be interested in registering
to access and use this data system.

Answer
1. Strongly Agree
2. Disagree
3. Agree
4. Strongly Disagree
5. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 2.429
[1.706 - 3.152]
Deviation: 0.976

Count
2
0
5
0
0
7
Standard Error: 0.369

Percent
28.57
0.00
71.43
0.00
0.00
100.00
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Q2. c. This program will likely increase communication between providers.

Answer
1. Strongly Agree
2. Disagree
3. Agree
4. Strongly Disagree
5. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 2.429
[1.846 - 3.011]
Deviation: 0.787

Count
1
2
4
0
0
7
Standard Error: 0.297

Percent
14.29
28.57
57.14
0.00
0.00
100.00
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Q2. d. This prescription monitoring program will not have much impact.

Answer
1. Strongly Agree
2. Disagree
3. Agree
4. Strongly Agree
5. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 2.857
[2.577 - 3.137]
Deviation: 0.378

Count
0
1
6
0
0
7
Standard Error: 0.143

Percent
0.00
14.29
85.71
0.00
0.00
100.00

139
Q3. In general (not just for you or your practice) - so far, how have the benefits of the
PDMP compared to the drawbacks?

Answer
1. benefits exceed the drawbacks
2. benefits and drawback are about equal
3. drawbacks exceed the benefits
4. I have no idea
Total
Confidence Interval @ 95% : Standard
Mean: 1.000
[1.000 - 1.000]
Deviation: 0.000

Count
7
0
0
0
7
Standard Error: 0.000

Percent
100.00
0.00
0.00
0.00
100.00
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Q4. In general (not just for you or your practice), how useful has the PDMP been so far?
How useful is the PDMP......

*** Overall Matrix Scorecard: In general (not just for you or your practice), how useful has the
PDMP been so far? How useful is the PDMP......
Question
Count
Score
1. a. ...in helping
7
1.000
clinicians and
pharmacies to
monitor patients
"controlled substance
prescriptions?"
2. b. ...in helping to
7
1.429
control "doctor
shopping" by patients
seeking to access or
abuse controlled
substances?
3. c. ...in helping
7
1.286
providers consult with
each other about
possible prescription
abuse by patients?
Average
1.238
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****individual options analyzed:
Q4. a. ...in helping clinicians and pharmacies to monitor patients’ controlled substance
prescriptions?

Answer
1. Very useful
2. Somewhat useful
3. Not useful
4. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 1.000
[1.000 - 1.000]
Deviation: 0.000

Count
7
0
0
0
7
Standard Error: 0.000

Percent
100.00
0.00
0.00
0.00
100.00
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Q4. b. ...in helping to control doctor shopping by patients seeking to access or abuse
controlled substances?

Answer
1. Very useful
2. Somewhat useful
3. Not useful
4. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 1.429
[1.033 - 1.825]
Deviation: 0.535

Count
4
3
0
0
7
Standard Error: 0.202

Percent
57.14
42.86
0.00
0.00
100.00
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Q4. c. ...in helping providers consult with each other about possible prescription abuse by
patients?

Answer
1. Very useful
2. Somewhat useful
3. Not useful
4. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 1.286
[0.726 - 1.846]
Deviation: 0.756

Count
6
0
1
0
7
Standard Error: 0.286

Percent
85.71
0.00
14.29
0.00
100.00
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Q5. Considering this program, and from your own knowledge of the program and its goals,
please indicate how much you agree or disagree with the following statements. * Please
choose one answer per statement.

*** Overall Matrix Scorecard: Considering this program, and from your own knowledge
of the program and its goals, please indicate how much you agree or disagree with the
following statements. * Please choose one answer per statement.
Question
Count
Score
1. a. This program is
7
2.857
likely to improve
management of
patient prescriptions
for controlled
substances.
2. b. Over time, I think
7
3.000
most providers and
pharmacists will be
interested in
registering to access
and use this data
system.
3. c. This program will
7
2.571
likely increase
communication
between providers.
4. d. This prescription
7
2.571
monitoring program
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will not have much
impact.
Average

2.750

Q5. a. This program is likely to improve management of patient prescriptions for
controlled substances.

Answer
1. Strongly Disagree
2. Disagree
3. Agree
4. Strongly Agree
5. Dont know
Total
Confidence Interval @ 95% : Standard
Mean: 2.857
[2.346 - 3.368]
Deviation: 0.690

Count
0
2
4
1
0
7
Standard Error: 0.261

Percent
0.00
28.57
57.14
14.29
0.00
100.00

146
Q5. b. Over time, I think most providers and pharmacists will be interested in registering
to access and use this data system.

Answer
1. Strongly Disagree
2. Disagree
3. Agree
4. Strongly Agree
5. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 3.000
[3.000 - 3.000]
Deviation: 0.000

Count
0
0
7
0
0
7
Standard Error: 0.000

Percent
0.00
0.00
100.00
0.00
0.00
100.00
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Q5. c. This program will likely increase communication between providers.

Answer
1. Strongly Disagree
2. Disagree
3. Agree
4. Strongly Agree
5. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 2.571
[2.175 - 2.967]
Deviation: 0.535

Count
0
3
4
0
0
7
Standard Error: 0.202

Percent
0.00
42.86
57.14
0.00
0.00
100.00
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Q5. d. This prescription monitoring program will not have much impact.

Answer
1. Strongly Disagree
2. Disagree
3. Agree
4. Strongly Agree
5. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 2.571
[2.175 - 2.967]
Deviation: 0.535

Count
0
3
4
0
0
7
Standard Error: 0.202

Percent
0.00
42.86
57.14
0.00
0.00
100.00
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Q6. In general (not just for you or your practice) - so far, how have the benefits of the
PDMP compared to the drawbacks?

Answer
1. benefits exceed the drawbacks
2. benefits and drawbacks are about equal
3. drawbacks exceed the benefits
4. I have no idea
Total
Confidence Interval @ 95% : Standard
Mean: 1.167
[0.840 - 1.493]
Deviation: 0.408

Count
5
1
0
0
6
Standard Error: 0.167

Percent
83.33
16.67
0.00
0.00
100.00
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Q7. In general (not just for you or your practice), how useful has the PDMP been so far?
How useful is the PDMP....

**** Overall Matrix Scorecard: In general (not just for you or your practice), how useful
has the PDMP been so far? How useful is the PDMP....
Question
Count
Score
1. a. ...in helping
7
1.429
clinicians and
pharmacies to
monitor patients'
controlled substance
prescriptions?
2. b. ...in helping to
7
1.429
control "doctor
shopping" by patients
seeking to access or
abuse controlled
substances?
3. c. ...in helping
7
1.429
providers consult with
each other about
possible prescription
abuse by patients?
Average
1.429
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Q7. a. ...in helping clinicians and pharmacies to monitor patients’ controlled substance
prescriptions?

Answer
1. Very useful
2. Somewhat useful
3. Not useful
4. Don’t know
Total
Confidence Interval @ 95% : Standard
Mean: 1.429
[1.033 - 1.825]
Deviation: 0.535

Count
4
3
0
0
7
Standard Error: 0.202

Percent
57.14
42.86
0.00
0.00
100.00
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Q7. b. ...in helping to control doctor shopping by patients seeking to access or abuse
controlled substances?

Answer
1. Very useful
2. Somewhat useful
3. Not useful
4. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 1.429
[1.033 - 1.825]
Deviation: 0.535

Count
4
3
0
0
7
Standard Error: 0.202

Percent
57.14
42.86
0.00
0.00
100.00
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Q7. c. ...in helping providers consult with each other about possible prescription abuse by
patients?

Answer
1. Very useful
2. Somewhat useful
3. Not useful
4. Don't know
Total
Confidence Interval @ 95% : Standard
Mean: 1.429
[1.033 - 1.825]
Deviation: 0.535

Count
4
3
0
0
7
Standard Error: 0.202

Percent
57.14
42.86
0.00
0.00
100.00
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Q8. You have received this version of our survey because our records show that you have
registered online as a user, to request and access information on patients. Is this correct?

Answer
Count
Percent
1. not correct, I have NOT registered for an account
0
0.00
2. not sure
0
0.00
3. correct
7
100.00
Total
7
100.00
Confidence Interval @ 95% : Standard
Mean: 3.000
Standard Error: 0.000
[3.000 - 3.000]
Deviation: 0.000

155
Q8a. If answered yes in Question 8, for how long have you had an account?

Answer
1. 2 months or less
2. more than 2 months
3. not sure
Total
Confidence Interval @ 95% : Standard
Mean: 1.857
[1.577 - 2.137]
Deviation: 0.378

Count
1
6
0
7
Standard Error: 0.143

Percent
14.29
85.71
0.00
100.00

156
Q9. How would you characterize your use of the PDMP system?

Answer
1. I have never used it
2. very minimal user
3. moderate user
4. active and regular user
Total
Confidence Interval @ 95% : Standard
Mean: 3.571
[3.175 - 3.967]
Deviation: 0.535

Count
0
0
3
4
7
Standard Error: 0.202

Percent
0.00
0.00
42.86
57.14
100.00

157
Q10. How easy was it to register as a user?

Answer
1. Very easy
2. Somewhat easy
3. Somewhat difficult
4. Very difficult
Total
Confidence Interval @ 95%:

Mean: 1.143 [0.863 - 1.423]

Count
6
1
0
0
7

Standard Deviation:
Standard Error: 0.143
0.378

Percent
85.71
14.29
0.00
0.00
100.00

158
Q11. How easy has it been to access patient information?

Answer
1. Very easy
2. Somewhat easy
3. Somewhat difficult
4. Very difficult
Total
Confidence Interval @ 95%:
Standard Deviation: 0.488
Mean: 1.286
[0.924 - 1.647]

Count
5
2
0
0
7

Percent
71.43
28.57
0.00
0.00
100.00

Standard Error: 0.184

159
Q12. In the last 30 days, about how many separate patients have you accessed the PDMP to
monitor or check on prescription medication?

Answer
1. none
2. 1-5
3. 6-25
4. more than 25
Total
Confidence Interval @
Mean: 3.429
95%: [3.033 - 3.825]

Count
0
0
4
3
7
Standard Deviation:
Standard Error: 0.202
0.535

Percent
0.00
0.00
57.14
42.86
100.00

160
Q13. In the past 30 days, for which of the following reasons have you used the PDMP
system? *Please check all that apply.

Answer
Count
when prescribing a controlled substance for a
1.
7
new patient
when prescribing a new controlled substance for
2.
7
an existing patient
when a patient requests an early refill on a
3.
7
controlled substance
to assess controlled substance use for patients
4.
7
who might be over-using
5. some other reason
0
Total
28
Confidence Interval @
Standard Deviation:
Mean: 2.500
Standard Error: 0.215
95%: [2.078 - 2.922]
1.139

Percent
25.00
25.00
25.00
25.00
0.00
100.00

161
Q14. Some providers have reasons for not using the PDMP system more often. How much
do each of the following barriers keep you from using the system more?

**** Overall Matrix Scorecard: Some providers have reasons for not using the PDMP
system more often. How much do each of the following barriers keep you from using the
system more?
Question
Count
Score
1. a. Limitations with
7
4.000
internet access at
work
2. b. Nor enough time
7
4.000
3. c. Lack of benefit for
7
4.000
my office
4. d. Support staff not
7
4.000
being allowed to
access the system
under my account
5. e. Lack of training on
7
4.000
how to use the PDMP
6. f. The system is not
7
4.000
easy to use
Average
4.000

162
***individual option analyzed:
Q14. a. Limitations with internet access at work

Answer
1. Large barrier
2. Medium Barrier
3. Small barrier
4. Not a barrier
Total
Confidence Interval @ 95% : Standard
Mean: 4.000
[4.000 - 4.000]
Deviation: 0.000

Count
0
0
0
7
7
Standard Error: 0.000

Percent
0.00
0.00
0.00
100.00
100.00

163
Q14. b. Nor enough time

Answer
1. Large barrier
2. Medium Barrier
3. Small barrier
4. Not a barrier
Total
Confidence Interval @ 95%: Standard
Mean: 4.000
[4.000 - 4.000]
Deviation: 0.000

Count
0
0
0
7
7
Standard Error: 0.000

Percent
0.00
0.00
0.00
100.00
100.00

164
Q14. c. Lack of benefit for my office

Answer

Count
1. Large barrier
0
2. Medium Barrier
0
3. Small barrier
0
4. Not a barrier
7
Total
7
Confidence Interval @ 95%: Standard Deviation: Standard Error:
Mean: 4.000
[4.000 - 4.000]
0.000
0.000

Percent
0.00
0.00
0.00
100.00
100.00

165
Q14. d. Support staff not being allowed to access the system under my account

Answer
1. Large barrier
2. Medium Barrier
3. Small barrier
4. Not a barrier
Total
Confidence Interval @ 95%: Standard
Mean: 4.000
[4.000 - 4.000]
Deviation: 0.000

Count
0
0
0
7
7
Standard Error: 0.000

Percent
0.00
0.00
0.00
100.00
100.00

166
Q14. e. Lack of training on how to use the PDMP

Answer
1. Large barrier
2. Medium Barrier
3. Small barrier
4. Not a barrier
Total
Confidence Interval @ 95% : Standard
Mean: 4.000
[4.000 - 4.000]
Deviation: 0.000

Count
0
0
0
7
7
Standard Error: 0.000

Percent
0.00
0.00
0.00
100.00
100.00

167
Q14. f. The system is not easy to use

Answer
1. Large barrier
2. Medium Barrier
3. Small barrier
4. Not a barrier
Total
Confidence Interval @ 95%: Standard
Mean: 4.000
[4.000 - 4.000]
Deviation: 0.000

Count
0
0
0
7
7
Standard Error: 0.000

Percent
0.00
0.00
0.00
100.00
100.00

168
Q15. In the past 30 days, which of the following actions have you taken as a result of using
the PDMP system to monitor prescription medications for your patients?* Please check all
that apply

Answer
Count
Percent
spoken with a patient about controlled substance
1.
7
13.73
use
2. contacted other providers or pharmacies
5
9.80
3. confirmed patient not misusing prescriptions
7
13.73
4. confirmed patent was doctor shopping
6
11.76
5. reduced or eliminated prescriptions for a patient
6
11.76
6. dismissed patient from practice
3
5.88
referred or recommended for substance abuse
7.
6
11.76
treatment
8. referred or recommended fro pain management
5
9.80
referred or recommended for anxiety (or other
9.
6
11.76
psychiatric disorder) management
10. something else
0
0.00
Total
51
100.00
Confidence Interval @ 95% : Standard
Mean: 4.824
Standard Error: 0.374
[4.090 - 5.557]
Deviation: 2.674

169
Q16. As a result of using the PDMP system, do you communicate more with any of the
following groups?

*** Overall Matrix Scorecard: As a result of using the PDMP system, do you communicate
more with any of the following groups?
Question
1. a. Clinicians and staff
inside my practice
2. b. Providers who
write prescriptions
3. c. Pharmacists
4. d. Patients

Count
7

Score
1.143

7

1.429

7
7
Average

1.286
1.000
1.214

*** individual option analyzed:

170
Q16. a. Clinicians and staff inside my practice

Answer
1. Yes, definitely
2. Yes, somewhat
3. No
Total
Confidence Interval @ 95% : Standard
Mean: 1.143
[0.863 - 1.423]
Deviation: 0.378

Count
6
1
0
7
Standard Error: 0.143

Percent
85.71
14.29
0.00
100.00

171
Q16. b. Providers who write prescriptions

Answer
1. Yes, definitely
2. Yes, somewhat
3. No
Total
Confidence Interval @ 95% : Standard
Mean: 1.429
[0.846 - 2.011]
Deviation: 0.787

Count
5
1
1
7
Standard Error: 0.297

Percent
71.43
14.29
14.29
100.00

172
Q16. c. Pharmacists

Answer
1. Yes, definitely
2. Yes, somewhat
3. No
Total
Confidence Interval @ 95% : Standard
Mean: 1.286
[0.726 - 1.846]
Deviation: 0.756

Count
6
0
1
7
Standard Error: 0.286

Percent
85.71
0.00
14.29
100.00

173
Q16. d. Patients

Answer
1. Yes, definitely
2. Yes, somewhat
3. No
Total
Confidence Interval @ 95% : Standard
Mean: 1.000
[1.000 - 1.000]
Deviation: 0.000

Count
7
0
0
7
Standard Error: 0.000

Percent
100.00
0.00
0.00
100.00

174
Q17. About which of the following topics do you communicate more with any of these
groups? * Please check all that apply.

Answer
1. I don't communicate more
2. Pain management
3. Drug interactions
4. Doctor shopping
5. Substance Abuse Treatment
6. Something else
Total
Confidence Interval @ 95% : Standard
Mean: 3.500
[3.075 - 3.925]
Deviation: 1.105

Count
0
6
7
7
6
0
26
Standard Error: 0.217

Percent
0.00
23.08
26.92
26.92
23.08
0.00
100.00

175
Q18. How useful would any of the following categories be as additional resources on the
PDMP website? * Please check all that apply.

*** Overall Matrix Scorecard: How useful would any of the following categories be as
additional resources on the PDMP website? * Please check all that apply.
Question
1. a. Guidelines around
pain management
2. b. Advice for seeing
patients with mental
health and substance
abuse issues
3. c. Recommendations
for seeing patients
with substance abuse
problems
4. d. Advice for seeing
patients dually
diagnosed with
mental health and
substance abuse
issues
5. e. Making referrals
for substance
treatment

Count
7

Score
1.000

7

1.000

7

1.000

7

1.000

7

1.000

176
6. f. Interacting with
patients using PDMP
data

7

1.000

Average

1.000

177
Q18. a. Guidelines around pain management

Answer
1. Very useful
2. Somewhat useful
3. Not useful
Total
Confidence Interval @ 95% : Standard
Mean: 1.000
[1.000 - 1.000]
Deviation: 0.000

Count
7
0
0
7
Standard Error: 0.000

Percent
100.00
0.00
0.00
100.00

178
Q18. b. Advice for seeing patients with mental health and substance abuse issues

Answer
1. Very useful
2. Somewhat useful
3. Not useful
Total
Confidence Interval @ 95% : Standard
Mean: 1.000
[1.000 - 1.000]
Deviation: 0.000

Count
7
0
0
7
Standard Error: 0.000

Percent
100.00
0.00
0.00
100.00

179
Q18 c. Recommendations for seeing patients with substance abuse problems

Answer
1. Very useful
2. Somewhat useful
3. Not useful
Total
Confidence Interval @ 95% : Standard
Mean: 1.000
[1.000 - 1.000]
Deviation: 0.000

Count
7
0
0
7
Standard Error: 0.000

Percent
100.00
0.00
0.00
100.00

180
Q18. d. Advice for seeing patients dually diagnosed with mental health and substance abuse
issues

Answer
1. Very useful
2. Somewhat useful
3. Not useful
Total
Confidence Interval @ 95% : Standard
Mean: 1.000
[1.000 - 1.000]
Deviation: 0.000

Count
7
0
0
7
Standard Error: 0.000

Percent
100.00
0.00
0.00
100.00

181
Q18. e. Making referrals for substance treatment

Answer
1. Very useful
2. Somewhat useful
3. Not useful
Total
Confidence Interval @ 95% : Standard
Mean: 1.000
[1.000 - 1.000]
Deviation: 0.000

Count
7
0
0
7
Standard Error: 0.000

Percent
100.00
0.00
0.00
100.00

182
Q18. f. Interacting with patients using PDMP data

Answer
1. Very useful
2. Somewhat useful
3. Not useful
Total
Confidence Interval @ 95% : Standard
Mean: 1.000
[1.000 - 1.000]
Deviation: 0.000

Count
7
0
0
7
Standard Error: 0.000

Percent
100.00
0.00
0.00
100.00

183
Q19. You received this version of our survey because our records show that you have not
registered online as a user. Is that correct?

Answer
1. correct
2. not correct
Total
Confidence Interval @ 95% : Standard
Mean: 2.000
[2.000 - 2.000]
Deviation: 0.000

Count
0
7
7
Standard Error: 0.000

Percent
0.00
100.00
100.00

184
Q20. What is your age?

Answer
1. under 30
2. 30-39
3. 40-49
4. 50-59
5. 60 or older
Total
Confidence Interval @ 95% : Standard
Mean: 3.286
[2.581 - 3.990]
Deviation: 0.951

Count
0
1
4
1
1
7
Standard Error: 0.360

Percent
0.00
14.29
57.14
14.29
14.29
100.00

185
Q21. What is your gender?

Answer
1. Male
2. Female
Total
Confidence Interval @ 95% : Standard
Mean: 1.857
[1.577 - 2.137]
Deviation: 0.378

Count
1
6
7
Standard Error: 0.143

Percent
14.29
85.71
100.00

186
Q22. What is your profession?

Answer
1. Nurse Practitioner
2. Physician Assistant
3. Physician
Total
Confidence Interval @ 95% : Standard
Mean: 1.571
[1.175 - 1.967]
Deviation: 0.535

Count
3
4
0
7
Standard Error: 0.202

Percent
42.86
57.14
0.00
100.00

187
Q23. What best characterizes your practice?

Answer
Count
1. Large private office (6+ practitioners
2
2. small private office (5+ practitioners)
3
3. academic practice
1
4. emergency room
0
5. safety net clinic (e.g., FQHC)
0
6. hospital-based clinic
1
7. Hospital inpatient primarily
0
8. other
0
Total
7
Confidence Interval @ 95% Standard
Mean: 2.429
Standard Error: 0.649
: [1.156 - 3.701]
Deviation: 1.718

Percent
28.57
42.86
14.29
0.00
0.00
14.29
0.00
0.00
100.00

